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ABSTRACT 
The injury border zone (IBZ), a region of transitional tissue between intact 
myocardium and the ischemic area, is often the site of lethal reentrant arrhythmia 
generation in post-myocardial infarction (MI) patients. Disruption to normal 
connexin43 (Cx43) localization at the intercalated disc (ID), separation of myocytes 
by activated fibroblasts and deposited scar tissue are thought to be factors that 
render the IBZ a pro-arrhythmic substrate, though there is a current need to better 
understand these changes so directed therapies can be developed. There are no 
clinically available therapies focused on the mechanistic changes in the IBZ. 
Additionally, generation of new compounds is challenged by the inefficiencies of 
the drug development pipeline, including the use of in vitro testing platforms that 
are of little relevance to human disease. In order to address the need for directed 
therapies and improved testing platforms, we developed a 3D in vitro aggregate 
model of the IBZ that was validated against a murine cryo-injury model of 
infarction. This model was used to examine the changes in heterocellular myocyte-
fibroblast interactions via Cx43 and cell organization patterns in response to αCT1 
– a Cx43 carboxyl-terminal mimetic peptide which was previously shown to alter 
cell organization in the IBZ of a murine cryo-injury model. Imaging results indicated 
that αCT1 increased fibroblast migration, as well as myocyte cohesion, as 
evidenced by increased cell clustering in aggregates at 72 hours. This was likely 
an effect of Cx43 adhesion properties. Optical mapping studies indicated that 
αCT1 could protect cryo-injured hearts against conduction delay through the IBZ 
iii 
 
in conditions of altered extracellular ion concentration. Subsequent analyses from 
a gap junction (GJ) intercellular communication (GJIC) assay indicated that this 
may be a result of altered communication, as αCT1 was found to decrease GJIC 
in myocyte-fibroblast connections and in fibroblast-fibroblast connections. This 
decrease in GJIC was correlated with an increase in Cx43 phosphorylated at 
serine 368 (pS368) in myocyte-fibroblast interactions in vitro an in vivo, which is 
known to decrease GJ channel conductance. Super-resolution imaging of GJ 
plaques revealed a novel sub-domain organization with respect to non-
phosphorylated Cx43 and Cx43 pS368. Together, the data provided in this 
dissertation describe the development of a novel in vitro model of the IBZ of 
relevance to drug response and disease mechanism that can be used as a high-
throughput testing platform for candidate compounds. These studies, furthermore, 
suggest the importance of Cx43 heterocellular interactions as a therapeutic target 
for reducing cardiac arrhythmias.   
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CHAPTER 1:  INTRODUCTION 
1.1   Myocardial infarction and the injury border zone – clinical problem and 
significance 
Heart disease is the number one killer of people worldwide, causing an estimated 
17.5 million deaths in 2012 (Fig. 1-1A) [1]. Ischemic heart disease – the cause of 
myocardial infarction – is responsible for over 7.2 million deaths each year (Fig. 
1.1B) [2]. In the western world, cardiovascular disease (CVD) is a major health and 
economic burden, responsible for three quarters of a million deaths in the United 
States alone [3], with indirect costs totaling over $200 billion [3]. However, over 
three quarters of deaths from cardiovascular disease (CVD) occur in low- and 
middle-income countries, because of the lack of access to primary care and early 
detection programs in contrast to those that are available in high-income countries 
(Fig. 1.1). These health issues create a heavy economic burden on these low- and 
middle-income countries. For example, the annual direct costs of CVD in China 
comprise 4% of their gross national income, estimated at more than $40 billion [4]. 
Projections from the World Heart Federation suggest that the burden of CVD in 
developing countries will rise to match that seen in industrialized countries 
because of increased urbanization and the associated lifestyle changes [4,5]. 
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Figure 1-1. Prevalence of cardiovascular disease worldwide. A) Total number of deaths 
from CVD by region in 2008. B) Total number of deaths from ischemic heart disease (which 
encompasses MI) by region in 2008. Reproduced from [1]. 
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Commonly known as heart attack, myocardial infarction (MI) is the death of cardiac 
tissue caused by prolonged ischemia [6]. It is most often caused by rupture of an 
atherosclerotic plaque with thrombus formation in a coronary vessel, blocking the 
blood supply to a portion of the myocardium (Fig. 1-2A). After the onset of 
ischemia, cell death occurs in minutes to hours. The extent of damage can be 
determined by factors such as location of the thrombus in the coronary vascular 
tree, the extent of collateral circulation to the ischemic zone, preconditioning, and 
reperfusion. A fully-healed infarct, as seen in Figure 1-2B, may not differentiate 
until 5 to 6 weeks after the MI [6]. Infarct size in a major predictor of outcome in MI 
patients [7]. Large infarcts result in extensive cardiac remodeling, including 
changes in gross morphology, histology, and molecular function/interactions [8]. 
Part of the remodeling process after MI includes excessive collagen deposition in 
the injured area of the myocardium, which prevents wall rupture, but generates a 
new non-contractile tissue that can no longer actively longer contribute to the 
mechanical pump function of the heart. Replacement fibrosis occurs in the area of 
injured myocardium, where collagen is deposited by activated fibroblasts (aka 
myofibroblasts). MI often results in reduced systolic and diastolic function and can 
predispose patients to arrhythmias because of the extensive remodeling that 
occurs [9]. Though an infarct may be healed by 5-6 weeks, the remodeling process 
is often ongoing; with continued dilation, heart function deteriorates over time, 
leading to heart failure and the eventual death of the patient [10]. 
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Figure 1-2. Myocardial infarction. A) A plaque rupture and thrombus blocking blood flow 
to a portion of the myocardium is the most common cause of acute MI. B) An infarcted 
human heart with a healing infarcted area indicated by arrows. Reproduced from [6] and 
[328]. 
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Bordering the infarct area is the injury border zone (IBZ), which is a few cell layer-
thick area of transition between the scar and the viable myocardium. The changes 
in tissue electrophysiological properties, cell organization, collagen deposition, and 
inefficient removal of toxic biochemical products, among other factors, can 
contribute to the generation of lethal arrhythmias in the IBZ [11–13]. The structural 
and biophysical changes that occur in the IBZ will be discussed in depth below. 
Standard of care for acute MI is focused on restoring blood flow to the ischemic 
tissue. Early treatment for MI may include oxygen therapy, aspirin and nitroglycerin 
to improve blood flow, as well as treatment for pain. Thrombolytics may be 
administered to dissolve the clot causing the MI, though this treatment is most 
effective within a few hours of the clot forming. Coronary angioplasty may be used 
acutely to open the blocked artery and a stent may be placed to maintain patency 
of the blood vessel. Pharmacological treatments such as beta blockers, 
angiotensin converting enzyme (ACE) inhibitors, and anti-coagulants may also be 
given [14]. More patients in the developing world are surviving MI due to improved 
clinical interventions, though the frequency of re-hospitalization is high [3]. While 
clinical interventions for acute MI are focused on dissolving the clot and 
reestablishing blood flow, there are few therapies focused on supporting healing 
of the heart, let alone regeneration of lost tissue and cells. 
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1.2   Structure and biophysical properties of connexins and gap junctions 
The connexin proteins that form gap junctions (GJs) are thought to be responsible 
for spread of electrical signals and subsequent coordinated contraction of the 
heart. GJs are present in nearly all mammalian tissues, and they serve an 
important function in direct intercellular communication, coordinating events in 
tissues and between cells. The connexin proteins that comprise GJs are tightly 
clustered together in the cell membrane, directly connecting the cytoplasm of two 
cells. This cytoplasmic continuity is the property that confers a functional 
syncytium. Work from Engleman in 1870 first described a functional syncytium 
when he reported a wave of contraction that traveled down a ureter after 
application of an electrical stimulus [15], a property later attributed to smooth 
muscle cells. Later work in the heart showed the ventricles could still contract 
rhythmically after being severed from innervation [16,17]. It was initially thought 
that a syncytium involved fusion of a portion of the membranes of adjacent cells, 
though later electron microscopy studies in mouse heart and liver showed that an 
electron dense tracer added during tissue processing filled the small “gap” 
between the membranes of two adjacent cells (Fig. 1-3A) [18] and in en face GJs 
between two cells, the tracer outlined the hexagonal array of the GJ plaque 
structure (Fig. 1-3B). It was Dewey and Barr that first suggested that these 
structures were sites of electrical coupling between cells [19,20]. 
7 
 
GJs are comprised of connexin proteins. Six connexin proteins oligomerize to form 
a connexon, or hemichannel, in the membrane of a cell. Two hemichannels from 
adjacent cells dock to form a GJ channel. Tens to thousands of GJ channels 
aggregate into a GJ plaque (Fig. 1-3 and Fig. 1-4A) [19,21,22]. In mammals, there 
are 22 known members of the connexin family of proteins, which can combine to 
form homotypic or heterotypic GJ channels (Fig. 1-4B) [23,24]. Connexins are a 
membrane tetraspan protein with intracellular amino- (N-) and carboxyl-terminal 
(C-terminal) domains. Within the four transmembrane domains are two 
extracellular loops and one cytoplasmic loop (Fig. 1-4C). The various connexin 
isoforms are named for their molecular mass, ranging in size from 25 to 60 kDa 
[25,26]. Much of the four transmembrane domains are conserved, with variability 
between the isoforms coming from differences in the C-terminus [25]. In the 
extracellular loop domains, disulfide bonds between cysteine residues are thought 
to be involved in docking of connexons between adjacent cells (Fig. 1-4C) [26], 
potentially playing a role in cell adhesion. Sequence similarity between different 
isoforms of the molecule allows connexins to form heterotypic channels, where the 
GJ channel is comprised of a connexon of different protein isoforms contributed by 
each cell (Fig. 1-4B) [27]. Sequence similarity in the transmembrane regions of the 
protein allows formation of heteromeric channels, where each connexon is made 
up of different isoforms of connexins (Fig. 1-4B) [28]. 
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Molecules of less than 1 kD in size can passively diffuse through a GJ channel, 
including water, metabolites, second messengers, nucleotides, and ions mediating 
the spread of electrical signals [29–31]. Hemichannels, or connexon channels that 
are located in the cell membrane, can also function in intracellular-extracellular 
Figure 1-3. Electron microscopy of GJs. A) Work by Revel and Karnovsky used 
lanthanum, an electron dense tracer, that revealed the 'gap' between the two membranes 
that gap junctions would come to be named for. B) The lanthanum tracer revealed a 
hexagonal array structure (‘j’ and higher magnification in inset), when used on tangential 
sections through the gap junction plaque. Reproduced from [18]. 
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exchange of these same molecules. While all connexins act as nonselective 
channels, passage of solutes through the channel may differ between compounds 
of similar chemical composition [32]. Selectivity, conductance, and gating of GJ 
channels can vary slightly between isoforms of connexins, and these properties 
are sensitive to voltage, chemical changes, and pH [32,33]. Other factors affecting 
the permselectivity of channels include phosphorylation and formation of 
heterotypic and heteromeric channels. The C-terminus and intracellular loop are 
thought to be largely responsible for differences in function between different 
isoforms of connexins. The C-terminus interacts with numerous proteins and 
contains many phosphorylation sites that can play roles in altering intercellular 
communication through direct changes in protein trafficking, distribution, 
degradation, and post translational modification [26,34,35]. 
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Figure 1-4. Molecular structure of the GJ. A) Connexin proteins assemble into 
connexons. Connexons from adjacent cells dock to form an intercellular GJ channel in the 
membranes of adjacent cells. B) GJs may form heterotypic or heteromeric channels, which 
can affect their permselectivity. C) Connexins have four transmembrane domains, a C-
terminus that interacts extensively with other proteins, and extracellular loops with 
disulfide bonds that may play a role in adhesion. Reproduced from [26,30]. 
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Though there are no reports discussing adhesive properties of connexins in the 
heart, several studies in the nervous system detail the function of connexins in 
intercellular adhesion. Cellular adhesion of a glioma cell line increased when 
transfected with Cx43, and this occurred independently of GJ channel function 
[36]. When antibodies directed against the extracellular loops of connexin were 
added, aggregation of Cx43-expressing cells was reduced. Connexin-mediated 
adhesion is also known to be required for radial migration of cells in the developing 
cortex [37]. In C6 glioma cells and HeLa cells (cells which do not normally interact), 
transfection of both cell types with Cx43 enabled adhesion to occur between the 
cells types in a short-term suspension aggregation assay [38]. Aggregation did not 
occur in untransfected cells. 
In 1970, Steinberg postulated that cells could sort due to differences in intercellular 
adhesion strengths [39]. In theory, cells with higher intercellular adhesion forces 
would sort to the center of co-culture aggregates, leaving the cells with lower 
adhesion forces on the outside. Foty and Steinberg later showed that expression 
of different levels of cadherins in cells provided evidence in favor of this hypothesis, 
as cells expressing higher levels of cadherins sorted to the inside of co-culture 
aggregates [40]. If connexins are involved in adhesion, then different levels of 
connexins between cells may also account for some level of sorting. More recent 
work demonstrated that this is, indeed, the case, as altering Cx43 in multiple cell 
lines led to changes in cell aggregate formation [41]. Sterically inhibiting Cx43 
docking with an antibody directed against the second extracellular loop of Cx43 
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slowed aggregation of cells, while enzymatic digestion of cellular adhesion 
molecules and N-cadherin neutralizing antibody decreased cell aggregation a 
comparable amount to inhibiting connexins. Interestingly, treating cells with Gap26 
– a Cx43 mimetic peptide that blocks gap junction intercellular communication 
(GJIC) but does not inhibit docking – accelerated cellular adhesion [41]. These 
data provide evidence that Cx43 does indeed have adhesive properties, and it may 
be that altered levels of Cx43 in the heart post-MI change patterns of cell migration 
and cohesion. 
 
1.3   Regulation of gap junction intercellular communication 
Several factors influence GJIC, including plaque size, phosphorylation, and 
formation of heterotypic and heteromeric channels. Additionally, there are several 
known compounds and peptides that can alter GJIC. 
From production through degradation of connexin proteins, the half-life of connexin 
proteins is measured at 1-5 hours [42,43], though in neonatal rat ventricular 
myocytes (NRVMs), it is reported to be 1-2 hours [44–46]. Regulation of GJ 
formation and degradation is likely important in control of GJIC. After transcription 
into mRNA, connexins are co-translated into the membrane of the endoplasmic 
reticulum (ER), where protein folding occurs [47,48], disulfide bonds are formed 
[49–51], and connexons are formed when individual connexin proteins oligomerize 
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[52]. Oligomerization may also occur in the trans-golgi compartment [53,54]. 
Phosphorylation of connexins, which will be discussed in detail below, and other 
post-translational modifications occur in the golgi compartment [44]. Additionally, 
Cx43 is known to be trafficked to the membrane via a microtubule-dependent 
mechanism [26,55]. 
Connexin proteins are then inserted throughout the membrane, diffuse laterally, 
and are incorporated into GJ plaques [26,52,56]. In the non-junctional region 
surrounding the plaque, called the ‘perinexus,’ connexon incorporation into the GJ 
plaque is constrained by interaction with Zonula Occludens-1 (ZO-1; discussed 
below) [57]. Single channel recordings of human Cx43 GJs expressed in a human 
liver cell line showed two unitary conductance states:  one at 60-70 pS and one at 
90-100 pS. The decreased conductance state was correlated with Cx43 
phosphorylation [58]. Formation of heterotypic and heteromeric channels leads to 
complex changes in channel conductance [59–64]. For example, heterotypic 
Cx43/45 channels had a conductance that was the sum of each of the hemichannel 
conductances [65], while conductance of homotypic and heterotypic channels 
comprised of two connexin subtypes are dissimilar [61,63,64]. 
Communication between adjacent cells can also be regulated by increasing the 
number of channels in a GJ plaque [66]. Work from our lab showed that in Cx43-
expressing HeLa cells, an increase in GJIC due to increased plaque size 
happened at the expense of hemichannel communication [57]. While connexons 
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are likely added to the plaque by lateral diffusion in the membrane, they are 
removed from the center of the plaque [67,68] as annular junctions – sections of 
GJs that span both cell membranes [69,70]. GJs are then degraded by 
proteasomal and lysosomal pathways [42,43,52]. 
Connexins are known to interact with many other proteins that affect their 
trafficking, lifecycle, function, and organization. The C-terminal binding partners of 
Cx43 have been shown to affect its secondary structure. Extensive reviews on the 
subject can be found here: [71,72]. Figure 1-5 illustrates the binding partners of 
Cx43. Work from the Gourdie lab and others suggests that accretion and stability 
of GJ channels can be regulated by Cx43-interacting proteins like Src and ZO-1 
[73–79]. For the purpose of relevant background for this project, we will focus on 
ZO-1 interactions with the Cx43 C-terminus, as well as other interactions that can 
regulate GJIC. 
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Cx43-ZO-1 interaction plays a key role in regulating GJ organization and 
remodeling and, as such, has been studied extensively [57,73–77,80–85]. Work 
from our lab suggested a role for ZO-1 in the control of GJ plaque size, as ZO-1 
was found primarily localized to the edges of GJ plaques in immunolabeling studies 
[86]. A tool developed in our lab to investigate the interaction between Cx43 and 
Figure 1-5. Cx43 interacting proteins. Connexins interact with many proteins (bottom 
half of membrane) and are phosphorylated by many kinases (top half of membrane). 
Reproduced from [52]. 
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ZO-1 was a peptide mimetic of the Cx43 C-terminus [77]. This peptide – αCT1 – 
contains an amino (N)-terminal biotin tag, an antennapedia internalization 
sequence, and the nine most extreme C-terminal amino acids – a known PDZ 
binding ligand mediating interaction with the ZO-1 PDZ2 domain (Fig. 1-6). A 
control peptide of the same C-terminal amino acids, but in reverse order was used 
in further experiments. In these experiments, it was found that treatment of 
neonatal rat cardiomyocytes with αCT1 decreased co-localization of ZO-1 at the 
edge of GJs and increased plaque size [77]. This reduced interaction between 
Cx43 and ZO-1 did not alter total Cx43 levels in cells, but did result in a shift in the 
pools of Cx43 so that more Cx43 was located at the interface between two cells 
and less was located in intracellular pools. Together, these data suggest that 
Cx43-ZO-1 interaction at the GJ plaque periphery may regulate GJ size by 
controlling the rate at which hemichannels transition into the GJ plaque. 
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Figure 1-6. αCT1 interrupts binding of ZO-1 to the Cx43 C-terminus. A) ZO-1 normally 
binds the Cx43 C-terminus. αCT1 was developed to investigate this interaction. αCT1 is a 
peptide mimetic of the Cx43 C-terminus attached to an antennapedia cell-internalization 
sequence. B)When added to cells, αCT1 crosses the cell membrane and bind to ZO-1, 
inhibiting the interaction of Cx43 and ZO-1. Reproduced from [329]. 
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Further studies in our lab showed that this Cx43-ZO-1 interaction occurred at the 
‘perinexus’ – a specialized domain around the GJ plaque. In this domain, it was 
proposed that the function of Cx43-ZO-1 interaction is to control hemichannel to 
GJ transition [57]. ZO-1 may, therefore, control the balance between hemichannel-
mediated communication with the outside of the cell and GJIC. Accordingly, these 
studies showed that decreased Cx43-ZO-1 interaction led to increased GJ-
mediated dye transfer between cells and decreased hemichannel dye uptake [57]. 
This parallels the long-held view that GJs are assembled from connexons added 
at the edges of the GJ plaque [67,87]. 
Another important type of intermolecular interaction of the Cx43 C-terminus is that 
of the numerous enzymes that can interact to phosphorylate residues of the tail. 
These are involved in regulating gating of connexins. Most connexins are 
phosphoproteins [88], and most phosphorylation events occur after membrane 
delivery [89]. While the phosphorylation events of connexin proteins are too 
extensive to be covered in depth here, the focus will be on phosphorylation of 
Cx43, as this is where most study of this phenomena has been done. A metabolic 
labeling study showed that Cx43 arrived at the membrane mostly 
unphosphorylated, and progressive phosphorylation of Cx43 paralleled 
incorporation into GJs [90]. Along these lines, dephosphorylation of connexins has 
been linked to degradation [42]. Phosphorylation plays roles in connexin turnover, 
GJIC, and cell and tissue pathophysiology, though this varies by cell type [88]. 
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The Cx43 C-terminus has 12 serine residues and two tyrosine residues that are 
known to be phosphorylated (Fig. 1-7A) [91]. The phosphorylation events of the 
Cx43 C-terminus are reviewed extensively by others and can be found here: 
[35,91–94]. Phosphorylation of Cx43 happens at different points throughout its 
lifecycle [90,95]. Various degrees of phosphorylation lead to changes in 
electrophoretic ability, and the protein separates into three major bands on 
Western blots: P0, P1, and P2. P0 is non-phosphorylated, and P1 and P2 are 
progressively phosphorylated and migrate more slowly (Fig. 1-7B). To some 
extent, Cx43 may be phosphorylated before it is inserted into the membrane 
[96,97]. Cx43 is known to be phosphorylated by non-receptor- and receptor protein 
tyrosine kinases, mitogen-activated protein (MAP) kinase, and elevated cAMP 
[91]. Protein kinase C (PKC) is known to increase Cx43 phosphorylation and 
decrease GJIC in numerous cell types [98–101]. Previous reports in NRVMs 
suggest that PKC activation increases [102] or causes no change to GJIC [103]. 
PKC phosphorylates Cx43 at S368 and S372. S368 is likely responsible for 
reduced GJIC and changes in single channel behavior [92], as PKC activation 
decreased single channel conductance of Cx43 to ~50 pS, whereas in cells with a 
Cx43-S368A mutation (i.e., substitution of serine for a non-phosphorylatable 
alanine (A) residue), the ~100 pS channel conductance state was present. Our lab 
has shown that PKCε activity is increased by αCT1, with a subsequent increase in 
Cx43 pS368 [104,105]. Though various diseases and compounds alter the 
phosphorylation status of Cx43, the biophysics of this process is not well 
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understood. For example, pS368 is often associated with the P0 band in Western 
blots, though it is unknown when this event occurs and whether this alters GJ 
plaque structure. 
 
1.4   Cardiac tissue organization and function in the normal heart 
Myocytes are responsible for the contractile function of the heart, while fibroblasts 
serve to generate the extracellular matrix (ECM) on which the heart is organized. 
While myocytes comprise up to 75% of the volume of the heart, non-myocytes are 
far more numerous, accounting for nearly two thirds of cells by number in rat [106] 
and human [107,108], although these cells may only account for 30% of cells by 
number in mice [109]. 
Myocytes are organized into sheets that are 3-5 cells thick and these muscle layers 
can slide against each other during ventricular contraction. ‘Fiber orientation’ or 
the orientation of myocytes along their long axis, varies from -45 in the epicardium 
to +45° in the endocardium relative to the ventricle horizontal plane [110,111]. 
Connexins are located primarily at the IDs on the short ends of myocytes, with 
some localized to lateral myocyte borders (Fig. 1-8A). This arrangement promotes 
anisotropic propagation of electrical signal through the myocardium [112]. 
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Figure 1-7. Cx43 C-terminal phosphorylation sites. A) There are many 
phosphorylatable amino acids on the Cx43 C-terminal tail. Each is highlighted here in 
colors corresponding to the enzyme responsible for its phosphorylation. B) 
Phosphorylation events are associated with changes in electrophoretic mobility of Cx43, 
and three bands result on Western blots. The P0 band migrates fastest and is thought to 
correspond to nonphosphorylated Cx43. The P2 band migrates slowest and incorporates 
multiple phosphorylation events. P1 is an intermediate band. Reproduced from [91] and 
[35]. 
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Figure 1-8. Connexin organization in the heart. A) Cx43 is localized primarily at the 
intercalated discs (IDs), and electrically connects adjacent myocytes. Inset: Cx43 is 
present in higher density at GJ plaque edges. B) Connexins 40, 43, and 45 are all found 
in heart and their expression varies by region of the heart, with Cx43 being the 
predominant connexin in the ventricle. Reproduced from [330]. 
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Connexins in the heart are thought to be responsible for the spread of electrical 
signals. Conduction starts in the sino-atrial (SA) node and travels through the atria 
to the atrio-ventricular (AV) node. Here, conduction is delayed while the ventricles 
are filled, then electrical activation is propagated though the His-Purkinje system, 
down to the apex of the heart. Waves of excitation then travel from the apex up to 
the base through ventricular myocardial tissues, being conducted through 
myocytes that are highly interconnected at IDs. The ID allows for sequential 
activation and contraction of the muscle syncytia by allowing the passage of ions. 
The mammalian heart contains three types of connexin proteins in abundance: 
Cx40, Cx43, and Cx45 [113–116]. Local conduction differences and 
electrophysiological properties in the heart are thought to be largely accounted for 
by the variation in connexin distribution (Fig. 1-8B) [116]. Analysis of connexin 
localization using myocyte and fibroblast specific markers in rabbit ventricle 
showed that 95% of Cx43 was associated with myocytes, 7% with fibroblasts, and 
3% was found at the interface between the two cell types (Fig. 1-9A) [117]. 
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While the long-held view of electrical activation in the heart involves ion transport 
through GJs, ephaptic coupling – in which local ion concentration gradients are 
responsible for activation of adjacent cells – may also play a role [118]. Studies 
from our lab have demonstrated the presence of the cardiac voltage-gated sodium 
channel, Nav1.5, in the perinexus along with other structural, functional, and in 
silico data that provides evidence for this non-electrotonic form of coupling in the 
heart [119,120]. Computer models have shown that ephaptic effects may be seen 
in all areas of extracellular space, not just at the IDs between myocytes [121], 
leaving open the possibility for fibroblast involvement. 
Figure 1-9. Cx43 localization in the ventricle in normal heart and disease. A) In the 
normal heart, Cx43 (green) is highly expressed in myocytes (red). Fibroblasts (blue) also 
express some amount of Cx43 and can interact with myocytes via this protein. Vertical 
arrows show myocyte-myocyte connections (MM), horizontal arrows show fibroblast-
fibroblast (FF) connections, and angled arrowheads show MF connections. B) In the injury 
border zone (IBZ) of infarcted myocardium, Cx43 organization is disrupted and is 
increasingly found in myocyte-fibroblast interactions (left arrowhead), and in fibroblasts 
(angled arrowhead). Reproduced from [331] and [173]. 
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Cardiac fibroblasts are organized into thin sheets, interspersed between myocytes 
in the myocardium. Fibroblasts in situ have a large surface area, with electron 
microscopy studies estimating their surface area at >1500 µm2 [122]. A large 
membrane surface area would enable fibroblasts to extensively interact with 
adjacent cells. 
Cardiac fibroblasts were once thought of as a homogeneous population of cells, 
though recent studies have shown that these cells of mesenchymal origin derive 
from a number of sources. The majority of fibroblasts derive from the pro-
epicardium [123]. Fibroblasts also originate from the epicardium and endothelium 
by epithelial-to-mesenchymal transformation (EMT) [124,125] and endothelial-to-
mesenchymal transformation (EndoMT) [126–128], respectively, though the 
species-specific relative contribution of these populations is presently unknown.  
One caveat to studying cardiac fibroblasts that may directly relate to their 
developmental heterogeneity is the lack of a marker that is inclusive and specific. 
Proteins that have been used to identify fibroblasts – of both normal and activated 
phenotypes – include discoidin domain receptor tyrosine kinase-1 (DDR2) 
[129,130], vimentin [131–133], Transcription factor-21 (TCF21) [134,135], 
fibroblast specific protein-1 (FSP1) (which has turned out not to be fibroblast 
specific) [136], fibroblast activation protein (FAP) [137–139], Wilm’s Tumor 1 
(WT1), and α-smooth muscle actin (αSMA) [140,141]. Lack of a specific marker 
has made studying these cells in health and disease challenging. While one of the 
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primary functions of a fibroblast is to produce collagen, few studies have used this 
as a benchmark for identifying fibroblasts in either health or disease, though more 
recent studies have demonstrated the utility of collagen as a genetic marker of 
cardiac fibroblasts [141]. 
Fibroblasts, as a mesenchymal cell, have been pegged as having the primary 
structural role of producing the ECM ‘skeleton’ of the heart into which the cardiac 
cells are organized. While this function is required for maintenance of the normal 
myocardium, and for preventing rupture of the infarct area due to myocyte death 
after myocardial infarction, fibroblasts are known to have many other roles. 
Fibroblasts are extensively involved in biochemical signaling in the heart (reviewed 
here: [142–144]), but also contribute to electro-mechanical signal transduction 
[145,146], and can be electrotonically coupled to myocytes [21,147–149], as 
fibroblasts have been shown to express Cx40, 43, and 45 [150,151]. The field of 
myocyte-fibroblast electrotonic coupling, while far from new (some of the first 
reports of myocytes coupling to non-myocytes were by Goshima [152] in the late 
1960s), still has a lot of open questions. 
 
1.5   Changes in the post-myocardial infarction heart 
The myocardium does not have the ability to regenerate, so after MI, the significant 
loss of cardiac muscle is replaced by a scar. The healing response in the 
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myocardium has been reviewed extensively elsewhere (see: [153,154]). A brief 
review will follow. Cells in the ischemic area of the myocardium die and cardiac 
repair begins with the inflammatory response that clears the infarcted region of 
tissue of dead cells and debris and provides the proper biochemical signaling to 
heal the infarct. Fibroblasts are activated in the process and migrate into the wound 
to replace the lost myocytes and deposit excess ECM. This healing and scarring 
response, as in other wounds in the body, changes over time, though it rarely 
reaches an equilibrium state as this type of scarring injury is generally associated 
with declining (and irrecoverable) cardiac function. As the heart is less able to 
efficiently pump due to the loss of myocytes, the heart begins to dilate and 
myocytes hypertrophy, a process that can eventually deteriorate into heart failure 
– an ultimately fatal disease [6]. 
Fibroblasts post-MI release chemotactic factors like transforming growth factor-β 
(TGF-β) that recruit inflammatory cells into the ischemic tissue and activate 
fibroblasts [155–158]. Activation of fibroblasts leads to transdifferentiation to 
myofibroblasts and includes an initial increase in proliferation and migration, 
followed by increased synthesis of ECM proteins [159]. While this helps prevent 
the heart wall from rupturing after MI, these changes can alter normal conduction 
through the heart [160]. As described in the previous section, fibroblasts in the 
heart comprise a heterogeneous population of cells. Recent studies in various 
injury models have shed some light on the contribution of these relative 
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populations to pressure overload-induced fibrosis in the heart [141,161], though it 
is presently unknown how these populations contribute to healing after MI. 
Bone marrow derived cells are known to be recruited to the site of injury in many 
tissues in the body. Several studies of MI suggest that bone marrow derived cells 
make a large contribution (up to 60%) of fibroblast-like cells in the scar [162–165], 
though there is some debate as to whether the labeled cells in these models truly 
represent bone marrow derived cells. 
The IBZ is often the site of reentrant arrhythmia generation and there are several 
structural factors that contribute to this, including changes in cell and tissue 
organization and changes in Cx43 distribution. While the myocytes in the ischemic 
area die and are replaced with fibroblasts and the ECM these cells deposit, some 
of the myocytes in the IBZ survive. Structural remodeling in the IBZ involves an 
interspersion of myocytes with fibroblasts and ECM, leading to separation of 
myocytes and increased coupling between myocytes and fibroblasts (Fig. 1-9B) 
[11,166,167]. Additionally, increased deposition of ECM proteins leads to an 
altered structure that can separate cells, interrupting patterns of electrical coupling. 
Alterations in cell organization and coupling may contribute to the arrhythmogenic 
propensity of the IBZ [168]. 
In addition to reorganization of cells and increased deposition of ECM proteins 
post-MI, Cx43 reorganization to the lateral borders of myocyte membranes in the 
IBZ, as seen in Figure 1-9B, is thought to contribute to arrhythmias [112,169–171]. 
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One of the alterations in fibroblasts post-MI is an increase in connexin expression 
[167,172,173], which increases the ability for fibroblasts to be coupled to myocytes 
via GJs [167]. While myocyte-fibroblast coupling is relatively rare in the uninjured 
myocardium, immunolabeling studies show that this coupling is increased in the 
IBZ (Fig. 1-9) [173,174]. In multiple experimental animal models, conduction 
slowing is measured in the IBZ and scar [104,160]. 
In addition to its known function in transmission of electrical signals in the heart, 
Cx43 is known to be involved in the spread of injury signals. GJs in skin are 
implicated in the spread of injury signals [175], and are involved in inflammation, 
wound closure, and scarring (reviewed here: [176,177]). Accordingly, the 
knockdown of Cx43 in mouse skin has led to smaller wound sizes and faster rates 
of closure [178]. In our lab, application of the αCT1 peptide to excisional skin 
wounds in rats and pigs led to shorter times to wound closure and scar tissue with 
more normal histo-architecture [179]. This peptide has completed Phase I and 
Phase II clinical trials for wound healing in chronic non-healing diabetic foot ulcers 
[180] and venous leg ulcers [181], where the peptide led to significant decreases 
in ulcer size versus standard of care treatment alone. In other studies from our lab, 
cryo-injury size was increased in streptozotocin (STZ) diabetic mice compared to 
control mice receiving insulin, and this increase in injury size was associated with 
a decrease in Cx43 pS368 [182], suggesting that Cx43 pS368 is likely decreasing 
the conductance state of GJ channels and the subsequent injury spread in the 
heart. 
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A decrease in GJIC has been observed in the myocardium post-MI [183]. After 
ischemia or during cardiac hypertropy, density of GJs decreases in the ischemic 
area compared to the remote regions of myocardium [184]. Changes in GJ 
distribution in the IBZ seem to contribute to reentrant arrhythmia generation [185]. 
Decreased electrical coupling during acute MI has been correlated with 
dephosphorylation and reorganization of Cx43, as well as translocation from the 
cell surface to intracellular pools [186,187]. 
In the population of Cx43 that remains at the ID in an ischemic setting, there is an 
increase in phosphorylation at S368 (Fig. 1-10) [94]. Additionally, ischemic 
preconditioning has been shown to increase PKCε–mediated Cx43 
phosphorylation of S262 and S368, and prevent Cx43 lateralization following an 
ischemic insult [188]. Phosphorylation events in Cx43 are known to regulate 
channel effects like unitary conductance, so it may be that communication is 
reduced as a protective mechanism against injury spread from the ischemic area. 
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1.6   Attempts to heal the heart 
Cardiac disease models 
Models of cardiac disease – both in vivo and in vitro – are used extensively in 
research not only to better understand disease processes, but also as a model for 
testing pharmaceutical compounds. The commonly used left anterior descending 
(LAD) coronary artery experimental model of acute MI in mice is closely 
Figure 1-10. Cx43 phosphorylation in ischemic disease. Cx43 that is phosphorylated 
at serine 368 (pS368) is maintained at the IDs in ischemic conditions while Cx43 
reorganizes to the lateral myocyte borders. Reproduced from [94]. 
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representative of ischemic cell death as seen in humans [189,190]. However, due 
to differences in branching of the coronary arteries and collateral circulation in 
rodents, this model often leads to differences in size and shape of the infarct area 
and scar [191]. First reported by van den Bos and colleagues [190], a cryo-injury 
model of infarction is generated by creating an injury area by freezing the left 
ventricle. While the mechanism of cell death is different in the cryo-injury model 
from the ischemic model, cryo-injury creates an extensive IBZ that is a few cell 
layers thick, and an injury that is of repeatable size and shape, making it ideal for 
testing therapeutic compounds targeted at altering IBZ properties. More clinically 
relevant models include dog, pig [192,193], and sheep infarction [194], since these 
animals are closer to humans in size, structure, and heart rate. However, these 
large animal models are expensive, low throughput, and time consuming. 
Many in vitro models have been used to study cardiac disease processes. These 
models use NRVMs, embryonic chick myocytes, human embryonic stem cell-
derived cardiomyocytes, and induced pluripotent stem cell (iPSC)-derived 
cardiomyocytes [195]. These models include natural hydrogel-based models, 
synthetic scaffold-based models, and microdevice-based models [196]. An 
advantage of iPSC cardiac disease models is that they can often reproduce 
genetic cardiac diseases, as has been observed with familial dilated 
cardiomyopathy [197] and familial hypertrophic cardiomyopathy [198]. More 
recently, in vitro models of cardiac disease have been used to test pharmaceutical 
compounds that are already used clinically in order to develop models relevant to 
33 
 
certain cardiac disease conditions. Human iPSCs have been used to test both an 
ion channel blocker (verapamil) [199] and a β-blocker (metoprolol), using beat rate 
and mechanical motion to assess cardiac tissue function. Additionally, another β-
blocker (isoproterenol) and a human Ether-à-go-go-Related Gene (hERG) blocker 
(E-4031) were tested in this model [200]. However, further development of these 
models for testing of pharmaceutical compounds relevant to cardiac disease is 
needed. 
 
Cardiac tissue engineering 
Nearly 20 years ago the first engineered cardiac tissues were created from 
embryonic chick cardiomyocytes [201]. The field has seen immense growth since 
then with hundreds of papers being published each year on the subject, including 
the first report of cell sheets being implanted in a patient [202]. The history, 
development, and state of the art of this field have been reviewed extensively 
elsewhere (see: [203,204]). The following is a brief summary on the successes and 
challenges of the various techniques used to engineer cardiac tissue. 
Cardiac tissue engineering has its roots in culture of aggregated cardiac cells, 
generated by rotating culture by Moscona in 1959 [205]. These heart cells formed 
heart-like tissue that generated beating aggregates.  
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Hydrogels have been used since the 1980s and include a gelling matrix of natural 
proteins like collagen or Matrigel in a casting form [201]. These proteins induce 
cells to spread and form intercellular connections. The cells can contract and 
remodel the matrix in which they reside. Hydrogels that are anchored induce 
alignment of cells and enable constant mechanical strain of engineered tissues. 
The first anchored studies demonstrated the importance of mechanical forces in 
alignment of cells and proper engineered tissue development [206]. More recent 
studies have shown that electrical stimulation can also induce proper cell 
alignment and development of tissue structure [207]. 
A classical engineering approach to cardiac tissue engineering involves creation 
of a prefabricated matrix that is seeded with cardiac cells or cardiac progenitor 
cells. Various materials used to create matrices include natural and synthetic 
materials like alginate [208] and collagen [201], or polyglycolic acid [209], and poly-
L-lactic acid/polyglycolic acid composites [210], among others. These matrices can 
be made to any dimensions and easily manipulated in culture. This being said, 
synthetic scaffolds are challenged by limited diffusion capacity, inability to be 
remodeled (though some can be degraded), and toxic degradation products. 
Decellularizing whole hearts with detergents that do not affect matrix structure can 
provide natural cues to cardiac cells or cardiac progenitor cells for repopulation, 
though repopulation of these structures has proven difficult [211]. 
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Temperature-sensitive coatings on culture dishes allows cells to be grown in 
sheets and then detached [212]. These sheets can be stacked to generate beating 
3D tissues. While this scaffold-free technology generates a tissue that is suitable 
for transplantation, these tissues can be difficult to manipulate because of their 
mechanical properties. However, this technique continues to be developed for 
cardiac repair [213,214]. 
In addition to mechanical strain and electrical signals, in vitro development of 
cardiac tissues has indicated the importance of non-myocytes in the formation of 
functional tissues. Tissues using a combination of myocytes and fibroblasts 
develop higher forces [215] and better tissue structure and electrical activation 
threshold [216]. 
Another approach to cardiac tissue engineering involves injection of cells in a 
matrix in situ and relies on native signaling within the myocardium to induce 
differentiation and maturation of injected cells [217]. Many of these techniques 
have been used in some variation or combination to create engineered cardiac 
tissue. However, there are remaining challenges to developing and treating an 
injured heart to regain function, including cell sourcing, standardization of 
protocols, serum-free culture, tissue maturation, and testing to ensure consistency 
across various methods [204]. 
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Pharmaceutical development 
There a great number of pharmaceutical compounds used for cardiac disease. 
General classes of these drugs include anticoagulants, antiplatelet agents, ACE-
inhibitors, angiotensin II receptor blockers, angiotensin receptor neprilysin 
inhibitors, β-blockers, combined α- and β-blockers, calcium channel blockers, 
cholesterol lowering medications, digitalis preparations, diuretics, and vasodilators 
[218]. In 2010, global market sales reached $170 billion for cardiovascular drugs 
alone and growth was projected to hit $187 billion by 2016 [219]. Development of 
new drugs, however, is expensive and inefficient. For most compounds, it takes 
over a decade of research and nearly $5 billion per drug [220–222]. Additionally, 
in order to launch a single drug per year, 9 compounds on average need to enter 
Phase I clinical trials, 5 need to enter Phase II, and 2 need to enter Phase III trials 
[221]. 
Before drugs reach the preclinical animal-testing phase, they are typically 
screened in vitro using established and well-characterized cell lines. 2D in vitro 
cultures are not representative of the 3D tissue microenvironment in either health 
or disease, making this a poor model for investigation. Additionally, preclinical 
animal models are expensive, poorly predict outcomes due to interspecies 
variation in cardiac electrophysiology [223,224], and have led to drugs being 
withdrawn from the market because of previously unobserved cardiotoxic effects 
[225,226]. Human heart cells and tissue would provide more relevant models, but 
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are difficult to obtain and challenging to maintain in culture, so they are an 
unrealistic testing platform [227]. 
There is a great need for design of new testing platforms with the goals of reducing 
cost and time to approval, decreasing the number of drugs that make it past 
approval and are then removed from the market because of toxic effects, and 
reducing side effects. In the last 20 years, the US Food and Drug Administration 
approved 113 drugs for cardiology and vascular diseases, many of them generics 
of drugs that had come off patents [228]. Not a single one of these drugs is aimed 
at healing the heart, restoring lost cardiac function, or regenerating the 
myocardium. Much preclinical testing directly targeting regeneration or disease-
related signaling cascades exists [229]. A combination of these new therapies and 
development of novel testing platforms has the potential to transform the 
development of cardiovascular therapeutics. 
 
The effect of Cx43 C-terminal mimetic peptide on the healing heart 
We adapted the cryo-injury model for use in our lab [104], and we have determined 
that it produces an injury of reproducible size and shape, making it useful for testing 
of therapeutic compounds as fewer animals can be used to detect differences 
between treatments. We have shown that treatment of a murine cryo-injury with 
αCT1 led to reduced LV dilation, fewer inducible arrhythmias, lower arrhythmia 
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severity scores, increased ventricular depolarization times, and maintenance of 
Cx43 at intercalated discs between myocytes, which was associated with an 
increase in Cx43 pS368 [104,230]. 
To further investigate the changes in the myocardium that could be responsible for 
the improvements in physiological function, TTC staining of hearts 8 weeks after 
cryo-injury showed a trend of decreased scar volume for αCT1-treated hearts 
relative to reverse peptide and vehicle controls [231]. The difference was 
significant (p < 0.02) for the αCT1 and reverse comparison. Images through the 
base-apex axis along the middle of each scar were used to quantify scar depth 
and thickness of underlying myocardium. There was a trend of decreased scar 
depth and increased depth of underlying myocardium for αCT1-treated hearts, but 
the differences between treatment and controls were not significant. 
Masson’s trichrome staining of histological sections of the scar also indicated that 
fibrous organization of the scar in αCT1-treated hearts was more uniform than in 
control mice (Fig. 1-11A) [231]. This was seen as a more regular pattern of 
collagen deposition and increases in collagen alignment along the scar. Vascular 
structures in the scar tissue appeared to increase scar non-uniformity by acting as 
obstacles that caused local variations in the orientation of collagen fibers. 
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Figure 1-11. Masson’s trichrome images of cryo-injured hearts indicates a more 
uniform scar structure. A) αCT1 treated hearts (bottom) show a more uniform fibrous 
structure than reverse inactive peptide controls (top). B) This was quantified by examining 
parameters of the scar substructure. While no differences were seen between αCT1 and 
controls in scar thickness, collagen density, or fiber orientation, the coefficient of variation 
(COV) of these measurements was significantly lower in αCT1-treated hearts compared 
to controls, meaning scars were more uniform. While COV of vascular density did not differ 
between groups, the vascular density was significantly reduced in αCT1-treated hearts 
versus controls – a factor that may contribute to more uniform collagen fiber orientation. 
40 
 
A survey of scar structure parameters showed that scar thickness (measured as 
the epicardial to endocardial thickness through multiple points along the scar) was 
not significantly different between groups (Fig. 1-11B). Collagen density was 
measured as the area of collagen tissue normalized to total scar area in Masson’s 
stain. Collagen fiber orientation was measured at 20 different points within the 
scar. None of these measurements were significantly different between treatments 
and controls. 
We measured the coefficient of variation (COV = SD/mean) of each of these 
measurements (Fig. 1-11B). The COV of scar thickness is significantly reduced in 
αCT1-treated scars compared to controls, meaning that scar thickness is more 
uniform. The COV of collagen density is lower in αCT1-treated hearts, meaning 
collagen density is more uniform. The COV of collagen fiber orientation is lower in 
αCT1-treated hearts compared to controls, meaning collagen is more organized in 
a uniform direction. In all of these parameters, αCT1-treated hearts showed less 
variation than either reverse or vehicle controls. This suggests that, in hearts 
treated with αCT1, scars were more uniform. We measured vascular density and 
the COV of vascular density and found fewer vessels in the αCT1-treated scars. It 
may be that this reduction in vascular density is one of the reasons for lower 
variation in collagen orientation, as with decreasing vessel density, there are fewer 
structures for collagen fibers to negotiate. Overall, the quantitative data indicated 
that the histo-architecture of 8-week LV cryo-scars in αCT1-treated hearts was 
more uniform than that of controls. 
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At 8 weeks after cryo-injury, a definite IBZ approximately 5-10 myocyte diameters 
wide differentiated adjacent to cryo-injury scars. This narrow zone of myocardial 
cells exhibited increases in MLC2a immunolabeling and this was significantly 
increased in αCT1-treated hearts compared to controls (Fig. 1-12A,B). The IBZ 
was also characterized by interdigitation of collagen fibrils projecting from the scar 
between border zone myocytes (Fig. 1-13A). There were striking differences in IBZ 
structure between αCT1-treated and control hearts. In picrosirius red staining of 
control mice, collagen tended to interdigitate in fine patterns between myocytes in 
the IBZ, while in the  IBZ of αCT1-treated hearts, groups of myocytes appeared 
grouped together in coherent bundles, with myocytes less separated by strands of 
interstitial collagen than in controls (Fig. 1-13A). Additionally myocytes in the IBZ 
in αCT1-treated hearts appeared to be slightly larger and more uniformly sized 
than controls (Fig. 1-13B). When quantified in a 4 cell-thick layer adjacent to the 
scar, αCT1-treated hearts also showed significantly decreased variability (COV) of 
IBZ myocyte width (Fig. 1-12B). There was a tendency for the mean size of IBZ 
myocytes to be increased in the αCT1 group, but this trend was not significant 
(data not shown). The extent of both MLC2a immunolabeling was also significantly 
increased in the IBZ myocardium of the αCT1-treated group, as compared to 
control (Fig. 1-13A,B). 
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Figure 1-12. αCT1 treatment of cryo-injured hearts alters myocytes. A) αCT1-treated 
hearts (right) have an increased expression of Mlc2a in the IBZ 8 weeks after injury 
compared to controls (left). B) αCT1-treated hearts have an increased expression of Mlc2a 
(left), are comprised of a higher percentage of myocytes (center), and have more uniform 
myocyte size than control hearts (right). C) Reduced collagen density and less variation 
in myocyte size in the IBZ are associated with reduced systolic dilation. These histological 
changes are seen in αCT1-treated hearts. 
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Figure 1-13. αCT1 alters cell organization in the IBZ. A) Picrosirius red staining of scars 
revealed collagen deposition that separates individual myocytes in CTRL hearts, and this 
occurred to a lesser extent in αCT1-treated hearts. B) Mlc2a labeling of myocytes in the 
IBZ indicated more cohesive bundles of myocytes in αCT1-treated hearts while in CTRL 
IBZ, myocytes appear to be separated by non-myocytes. 
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Both echocardiography and scar morphometry were undertaken on mice subject 
to the cryo-injury. If we look at how these histological changes correlate with 
changes in physiological function, we find significant positive correlations between 
LV systolic dilation and collagen density, as well as LV systolic dilation and the 
coefficient of variation of myocyte width in the border zone (Fig. 1-12C). The first 
correlation may reflect that with increased collagen density the ability of the heart 
to dilate at systole is being impaired. More uniform myocyte size was also found 
to correlate with LV systolic dilation. A more uniform myocyte size signifies less 
variation in the contractile ability of these myocytes in the IBZ, and more even 
application of mechanical forces. Overall, this suggests that a lower collagen 
density in the scar and a lower variation in myocyte width in the IBZ are associated 
with improved physiological outcomes and both of these are changes seen in the 
αCT1-treated hearts. 
Overall the changes in cell organization and scar profile the IBZ with αCT1-
treatment raised the question as to whether αCT1 was altering cellular interactions 
in a way that led to improved physiological outcome. 
 
Study objectives and rationale 
Our objective is to develop an in vitro model of the IBZ that can be 1) validated 
against an animal model of infarction, 2) used as a platform for high-throughput 
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testing of potential therapeutic candidates to target the IBZ, and 3) used to gain a 
better understanding of heterocellular interactions in IBZ. 
The rationale for these studies is the need for disease-relevant and tissue 
structure-relevant in vitro testing platforms for candidate compounds and the lack 
of understanding of how heterocellular interactions render the IBZ a pro-arrhythmic 
substrate. Important design criteria for in vitro testing of pharmaceutical 
compounds of relevance to cardiac disease include: 1) A disease model system 
that sufficiently recapitulates key aspects of the cardiac disease; and 2) A disease 
model system that can accurately reproduce the drug response seen in vivo. 
Chapter 2 describes the development and validation of our novel model of the IBZ. 
It covers changes that we see in the model that reflect the changes in a cryo-injury 
model of infarction in mouse and begins exploration of the mechanism behind 
these changes. 
Chapter 3 describes the conduction-related changes in cryo-injured hearts treated 
with our Cx43 mimetic peptide in the presence of varying extracellular ion 
concentrations, the contribution of recruited bone marrow cells to the healing IBZ, 
and the effect of the peptide on GJIC. 
Chapter 4 describes the changes in myocyte-fibroblast interactions via Cx43 in 
vivo and in vitro and examines the GJ plaque sub-domain organization. 
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Chapter 5 is a stand-alone chapter. It briefly examines the role of Cx43 in healing 
and regeneration of skeletal muscle, and serves as a proof of principle in 
modulating the immune response to skeletal muscle satellite cells for muscle 
regeneration. 
Chapter 6 contains conclusions, discusses challenges and limitations, and gives 
future directions and recommendations. 
 
Significance and innovation 
Generation and validation of a novel in vitro IBZ model will provide a platform that 
enables us to better understand heterocellular interactions in the IBZ and the basis 
for future testing of novel therapeutic compounds. While 3D models have been 
used extensively to study tumor microenvironment and treatments, to our 
knowledge, no studies have been done in a 3D model of cardiac cells to examine 
cellular interactions. This project addresses a critical barrier to progress in 
development of cardiovascular therapeutics focused on regeneration and altering 
intercellular interactions. Successful completion of this project will change our 
knowledge of the disease state and will provide a better model for testing of 
therapeutics for post-MI patients that is directed at disease mechanism. 
These studies are innovative in that they seek to challenge the clinical paradigms 
by shifting treatment from a focus on prolonging life of post-MI patients to one of 
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cardiac regeneration and understanding mechanisms that go beyond attempting 
to stabilize cardiac function. A goal of this work is to also shift current research 
paradigms for drug development to using more clinically relevant models of 
disease for testing of therapeutic compounds. This has the potential to decrease 
cost by finding better treatments, making additional and ongoing treatments for 
patients unnecessary, and also to identify and remove non-efficacious or toxic 
compounds in development more quickly, reducing the cost of the drug 
development pipeline. These studies will accomplish this by creating novel 
methods for analysis that could lead to further development of instrumentation. 
Some of these methods are novel to the cardiovascular field, having been used in 
other fields for therapeutic development, while others are novel across all fields. 
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CHAPTER 2:  DEVELOPMENT AND VALIDATION OF A NOVEL IN VITRO 
MODEL OF THE CARDIAC INJURY BORDER ZONE 
 
2.1   Introduction 
The leading cause of death in the Unites States is cardiovascular disease (CVD), 
which was responsible for 787,000 deaths in 2011 [3]. Myocardial infarction (MI) 
alone caused over 157,000 deaths in 2011. Estimated direct and indirect costs of 
heart disease in 2010 was $204.4 billion, with MI being one of the most expensive 
diagnoses ($11.5 billion) [3]. While current clinical interventions have increased 
patient survival [3], there are few new candidate compounds for cardiovascular 
disease [232], not to mention the lack of available drugs focused on restoring heart 
function [229]. To shift treatment of cardiac disease from a focus on prolonging life 
to a focus on curing disease, development of new compounds directed at 
underlying disease mechanisms is critical. Until we understand disease 
mechanism better, have more disease-relevant models for evaluating drugs, and 
develop mechanistically based drugs, the therapeutic pipeline will continue to be 
challenged by a low number of candidate drugs.  
Mechanistically speaking, the injury border zone (IBZ) –  typically no more than a 
few cell layers thick – is often the site of lethal arrhythmia generation [11,233]. 
While cellular heterogeneity at the border zone is a critical predictive factor for 
arrhythmogenesis [234], the mechanism of this contribution remains to be 
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understood. Altered patterns of Cx43 protein [233] and changes in organization of 
myocytes and fibroblasts are key variations of the IBZ compared to healthy 
myocardium [173], though how these changes contribute to the re-entrant 
arrhythmias that occur at these pathogenic tissue loci remains to be understood. 
Our lab previously showed the effects of a Cx43 C-terminal mimetic peptide (αCT1) 
on healing of a cryo-injury model of infarction [104]. αCT1-treated hearts showed 
reduced LV dilation, fewer inducible arrhythmias, lower arrhythmia severity scores, 
increased ventricular depolarization times, and maintenance of Cx43 at 
intercalated discs between myocytes [104,230]. Examination of patterns of 
collagen deposition and myocyte and fibroblast localization in the IBZ of cryo-
injured hearts displayed a difference in patterns of cell organization (Chapter 1). It 
may be that αCT1 is altering heterocellular interactions in the IBZ in a way that 
decreases arrhythmogenesis, though this needs to be investigated directly. 
While animal models of infarction are used extensively and can accurately 
recapitulate important aspects of human disease (i.e. arrhythmias), these models 
are expensive, time-consuming, and low-throughput. These models are also not 
feasible for initial screening studies. Before drugs reach the pre-clinical animal 
model stage, extensive in vitro testing is involved in screening new candidate 
drugs, though most of this is done on cell lines in 2D culture, which is far from 
representative of actual human tissues. Frequently, drugs that demonstrate 
effectiveness in these systems are not clinically effective and contribute to the 
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meager 16% of compounds that make it through drug development and into the 
clinic and market [235]. 
In vitro testing allows direct control of cell types and can readily accommodate co-
culture models. Unlike in vivo systems, where many cell types are involved and 
cannot be controlled, in vitro co-culture models allow isolation of effects based on 
interactions of specific cell types. Additionally, 2D in vitro systems lend themselves 
to simple methods of examining cell interactions by technologies such as live cell 
imaging. While 2D cultures have a limited ability to simulate 3D tissue processes, 
development of a 3D in vitro heterocellular model of the IBZ would greatly 
contribute to the drug development pipeline and would provide a platform to 
examine myocyte-fibroblast interactions in disease. Development of a model that 
simulates disease-relevant tissue processes may help screen out ineffective 
compounds before they reach the expensive pre-clinical stage, leading to huge 
cost savings in drug development. 
The objective of the present study was to: 1) Develop and optimize a 3D in vitro 
model of the IBZ using primary cardiac cells; 2) Validate this model against known 
parameters of the IBZ; and 3) Evaluate the response to a small peptide therapeutic 
that was previously shown to improve cardiac function after experimental MI in 
mice [104]. This model is optimized to generate large numbers of technical 
replicates that are highly reproducible, to create aggregates of cells that are 
sufficiently small so they are not subject to necrotic cell death from oxygen 
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starvation, and to allow high-throughput live imaging in order to obtain relevant 
time-dependent data when testing a therapeutic compound. This model may be 
used as a platform to study new compounds. 
 
2.2   Methods 
Preparation of HeLa cell aggregates in rocking culture: HeLa and HeLa-Cx43 cells 
were cultured in DMEM (Hyclone) supplemented with FBS (Hyclone), 10 U/ml 
penicillin and 10 µg/ml streptomycin (Hyclone), and 2 mM L-alanyl-L-glutamine 
(Gibco) and maintained in an incubator at 37°C, 5% CO2. HeLa and HeLa-Cx43 
cells were mixed 1:1, seeded at 1x106 cells/well in agarose-covered chamber 
slides, and rocked at 0.25, 0.5, or 1 Hz. Media was changed daily. To image, 
aggregates were removed from wells, washed in PBS, fixed for 10 minutes at room 
temperature in 4% paraformaldehyde, washed in PBS, dried on gasketed slides, 
mounted in SlowFade Gold reagent (Life Technologies), and imaged on a Leica 
SP5 laser scanning confocal microscope (LSCM). 
Preparation of acrylamide and agarose micromolds: Micromolds (24-96 – small 
spheroids) from microtissues.com were filled with 2% UltraPureTM Agarose (Life 
Technologies) in normal saline. Molds were extracted and equilibrated in myocyte 
complete medium for 3 medium changes. For acrylamide micromolds, a 20% 
acrylamide mix was made of acrylamide stock, bis-acetate, PBS, water, and 
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TEMED. Fresh 2% ammonium persulfate was added and solution immediately 
pipetted into the micromolds and allowed to gel. Acrylamide micromolds were 
sterilized with 70% ethanol, rehydrated in PBS, and equilibrated with myocyte 
complete medium before use. 
Cell seeding and culture in micromolds: H9C2 cells (ATCC), an embryonic rat 
myocardium-derived cell line, were cultured in DMEM High glucose (4500 mg/L) 
with sodium pyruvate (110 mg/L) (Hyclone) supplemented with 10% FBS 
(Hyclone), 10 U/ml penicillin and 10 µg/ml streptomycin (Hyclone), and 2mM L-
alanyl-L-glutamine (Fisher) and maintained in an incubator at 37°C, 5% CO2. 
Aggregates were labeled with CellTracker Orange (CMRA) (Life Technologies), 
and seeded at 1,440-324,000 cells per micromold. This should result in aggregates 
from 50-300 µm diameter. To image, aggregates were spun out of the micromolds 
at 800 rpm for 5 minutes, washed in PBS, and resuspended in glycerol on a 
depression slide, or in a home-built gasket slide, making the gasket as thin as 
possible to accommodate the aggregates but still be able to image. Cells were 
then imaged on a Leica SP5 and aggregate diameters were measured from these 
images. 
Cell isolation and labeling: Primary cardiac neonatal rat ventricular myocytes and 
neonatal rat ventricular fibroblasts (NRVFs) were isolated from 2-day neonatal rats 
by digestion in trypsin (Worthington), Pancreatin (Fisher), Collagenase II 
(Worthington), and elastase (Fisher) in HBSS (Hyclone). Cells were separated on 
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a Percoll (GE Healthcare) gradient, and washed. Fibroblasts were seeded and 
cultured in DMEM (Hyclone or Gibco) supplemented with FBS (Hyclone), 10 U/ml 
penicillin and 10 µg/ml streptomycin (Hyclone), and 2 mM L-alanyl-L-glutamine 
(Fisher) and maintained in an incubator at 37°C, 5% CO2. Myocytes were labeled 
immediately in 2.5 µM CellTracker Orange (CMRA) (Life Technologies) in 
OptiMEM (Gibco) for 30 minutes and washed in myocyte complete medium (M199 
supplemented with 0.16% glucose (Sigma), 1x MEM vitamins (Gibco), 1x NEAA 
(Gibco), 1x MEM Amino acids (Gibco), 10 U/ml penicillin and 10 µg/ml 
streptomycin (Hyclone), 10% horse serum (Gibco), and 5% FBS (Hyclone). 
Myocytes were seeded at 30,000 cells per mold and allowed to aggregate for 48 
hours. Before seeding, fibroblasts were washed in PBS, labeled with 2.5 µM 
CellTracker Green (CMFDA) in OptiMEM (Gibco) for 30 minutes and washed in 
fibroblast medium. Fibroblasts were added at 48 hours at 30,000 cells per mold. 
Culture medium (including treatments) was changed every 24 hours. Aggregates 
were treated with 100 µM αCT1, reverse control peptide, or vehicle control. 
Cx43 mimetic peptides and aggregate treatment: Two peptides (American 
Peptide) were generated: αCT1 and a reverse sequence peptide (REV). These 
peptides contain an N-terminal biotin tag followed by the 16-amino acid 
antennapedia internalization vector (RQPKIWFPNRRKPWKK). Linked to the C-
terminal K of the antennapedia sequence is either the C-terminal 9-amino acids of 
Cx43 (RPRPDDLEI; αCT1) or the Cx43 C-terminal 9-amino acids in reverse 
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(IELDDPRPR; REV; Fig. 1-6). Aggregates were treated with 100 µM αCT1 or REV 
peptide in culture medium with daily medium changes. 
Live imaging of aggregates: Aggregates were imaged at 24, 48, and 72 hours after 
fibroblasts were seeded. An upright Leica SP5 LSCM equipped with a 20x dipping 
lens (Leica HCX Apo L 20x/0.5 UVI, 506147) was submerged in the well of a 24-
well plate containing each micromold (each micromold contained 96 wells, each 
with a single aggregate). Alternatively, an inverted Leica SP8 LSCM equipped with 
a heated, humidified, and CO2–injected incubation system and a 10x lens (Leica 
HC Plan Apo 10x/0.4 NA) was used to image aggregates in micromolds sitting in 
MatTek plates with no loss of optical clarity. 15 aggregates were imaged live and 
analyzed for various model parameters including size, cell migration, and cell 
number. 
Immunolabeling: Aggregates were washed in PBS, fixed for 10 minutes at room 
temperature in 4% paraformaldehyde, and washed 3x in PBS. The depression at 
the top of the micromold was filled with molten agarose and allowed to gel in order 
to prevent aggregates from being lost from micromold wells. Micromolds were 
placed in 30% sucrose (company) overnight, embedded in OCT and frozen. 
Micromolds were cryosectioned at 10 µm and dried on positively charged slides 
for 30 minutes prior to immunolabeling. Slides were either stored at -80°C or were 
immunolabeled immediately. Sections of aggregates were blocked with 1% BSA 
(Fisher Scientific), 0.1% Triton-X-100 (Fisher Scientific) in PBS. Sections were 
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immunolabeled for vimentin (Millipore) (1:1000), MF20 (DSHB) (1:100), pan-
cadherin (clone CH-19, Sigma C1821, 1:1000), or Cx43 (Sigma or Abcam). 
Labeling was viewed with AlexaFluor secondary antibodies and stained with 
Hoechst 33342 (Sigma; nuclear labeling), mounted, and imaged on a Leica SP5 
or SP8 LSCM equipped with a Leica Plan Apo 63x/1.4 NA oil immersion objective. 
Statistical analyses: All data were checked for normality by Shapiro-Wilk [236–
240]. Non-normal data were transformed to normality using Box-Cox. If data could 
not be transformed to normality, non-parametric tests were used. Normal data 
were examined by ANOVA. All statistical analyses were performed in Statistical 
Package for the Social Sciences (SPSS). 
 
2.3   Results 
Agarose micromolds allow generation of a high number of reproducible aggregates 
of uniform size that can be subjected to live imaging 
To produce a 3D heterocellular model of the IBZ, multiple techniques to generate 
cell aggregates were examined. HeLa cells and HeLa cells stably expressing Cx43 
(HeLa-Cx43) were used initially. The parental HeLa cell line is not known to 
express connexin proteins, though the HeLa-Cx43 cell line has been transduced 
to stably and heterologously express Cx43 [241]. These cells are representative 
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of myocytes and fibroblasts in the heart, as cardiac fibroblasts express low levels 
of connexin proteins [167,242], and myocytes express Cx43 abundantly [243,244]. 
First, hanging drop culture was tested by mixing equal numbers of myocytes and 
fibroblasts and pipetting them into holes punched in the silicone-coated lid of a 48-
well plate. Cells aggregated over time, and could be spun down into the wells. This 
method allowed only mixed-cell aggregates to be formed, and made manipulation 
of aggregates difficult (data not shown). Also, this method produced relatively small 
numbers of aggregates limiting progress rate. Second, rocker culture was tested 
on a heterocellular population of aggregrates. Agarose-coated chamber slides at 
various rocking speeds were seeded with HeLa-Cx43 and WT HeLa cells. A 
rocking speed of 0.25 Hz resulted in clumps with 10-20 cells. Increasing the 
rocking speed to 0.5 Hz resulted in clumps of 4-10 cells, with a few larger 
aggregates. Increasing rocking speed further to 1 Hz resulted in clumps of 15-20 
cells with many larger aggregates of cells. These larger aggregates of cells 
appeared to be ~150-275 µm in diameter (Fig. 2-1A), though size could not be 
precisely controlled. It also appeared that these larger clumps of cells likely 
aggregated from smaller clumps of similar cells, resulting in cell separation within 
the aggregates that could not be accurately regulated (Fig. 2-1B). Aggregates 
generated by rocker culture were fixed, washed in PBS, and dried onto slides with 
a gasket, then mounted and imaged. While this method did allow cells to be imaged 
at a magnification that nearly enabled discrimination of individual cells (Fig. 2-1), 
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this proved a relatively low-throughput method. Aggregates were also not able to 
be imaged live, as they could not be efficiently immobilized. 
In order to create cell aggregates of more precisely controlled and consistent size, 
micromolds from microtissues.com were tested (Fig. 2-2A) [245,246]. These molds 
can be filled with a non-adhesive, permeable material and a cell suspension can 
be seeded into the depression on the top of the mold. The cell suspension is 
allowed to settle and aggregate over time. One of the objectives in developing this 
model was to create a simple way to image live cells within these aggregates, as 
we would be able to track their organization over time. Therefore, we wanted a 
Figure 2-1. Heterocellular aggregate generation by rocker culture. A) Aggregate size 
cannot be precisely controlled at 1 Hz. B) Even mixing of heterocellular populations cannot 
be controlled at 1 Hz. 
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material for the micromolds that was optically transparent. While acrylamide was 
more transparent than Ultrapure agarose, tested cells frequently failed to properly 
aggregate, adhering to the sides of acrylamide microwells (Fig. 2-2B).  Ultrapure 
agarose (Fig. 2-2C) was found to provide an optimal substrate for promoting 
formation of aggregates, thus, we used this material for further development of our 
model of the IBZ. 
Optimization of aggregate size for the IBZ model involved testing a variety of cell 
seeding densities. To do this, we used a more cardiac-relevant cell line – H9C2 
cells – which are derived from embryonic rat myocardium. Aggregates of varying 
cell densities were seeded into micromolds and images were obtained (Fig. 2-3). 
Figure 2-2. Silicone molds can be used to generate microwells of optically 
transparent, permeable materials (A). B) Cells did not aggregate efficiently in 
acrylamide, and often adhered to the microwells. C) Cells in agarose micromolds 
aggregated efficiently and formed aggregates of uniform size. Scale = 200 µm. 
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The critical diffusion length of oxygen in tissues is around 200 µm [247], so this 
placed an upper limit on the size of aggregates, such that cells were able to 
exchange nutrients and waste and avoid the formation of necrotic zones at the 
center of aggregates [248]. Furthermore, while we determined that generating 
aggregates in a large range of sizes was possible, light scattering and lack of laser 
penetrance constrained our ability to image into H9C2 cell aggregates deeper than 
100 µm (Fig. 2-3). Thus, maintaining cell viability and the demands of the imaging 
technologies available to us set our optimal aggregate size limit at ~100 µm. 
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To generate a more cardiac-relevant model of the IBZ, we used neonatal rat 
ventricular myocytes (NRVMs) and neonatal rat ventricular fibroblasts (NRVFs) 
isolated from 2-day old rat pups. Aggregates were generated by two seeding 
Figure 2-3. Aggregate size can be controlled by varying cell seeding density into 
the micromolds (A). B) Imaging of larger aggregates was challenged by laser penetrance 
and light scattering when using standard confocal techniques. Scale = 200 µm and 100 
µm in A and B, respectively. 
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methods. In both methods, equal numbers of myocytes and fibroblasts were used. 
First, myocytes were labeled with CellTracker Orange (CMRA) dye and mixed in 
equal parts with fibroblasts that were labeled with CellTracker Green (CMFDA). 
This mixed-cell population was then seeded into equilibrated agarose micromolds 
and allowed to settle and aggregate (Fig. 2-4A). In the second method, myocytes 
were labeled with CellTracker Orange (CMRA) dye and seeded into micromolds 
to form a core of myocytes. Fibroblasts were cultured, then labeled with 
CellTracker Green (CMFDA), and seeded into the micromolds on top of the already 
Figure 2-4. 3D IBZ model incorporating myocytes and fibroblasts. A) Aggregates of 
evenly mixed cells maintained this organization in culture. B) Layered aggregates with a 
core of myocytes and a shell of fibroblasts led to changes over time in cell organization, 
as fibroblasts migrated to the center of aggregates. C) Treatment of the IBZ model with 
αCT1 led to increased fibroblast migration (p<0.05) over time. D) Myocytes appeared to 
be more cohesive in αCT1-treated aggregates, whereas fibroblasts separated individual 
myocytes in CTRL aggregates. This tendency could be measured by counting cluster 
number (p<0.05; E). Scale = 50 µm. 
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formed myocyte aggregates. This novel approach enabled the formation of an 
external shell (mantle) of fibroblasts around a central core of myocytes (Fig. 2-4B). 
Figure 2.5 shows immunolabeling for myocyte and fibroblast-specific proteins. 
MF20 and vimentin signal overlapped with the CellTracker labeling based on the 
Percoll separation of cells (e.g. vimentin labeling overlapped with CellTracker 
Green-loaded fibroblasts and MF20 labeling overlapped with CellTracker Orange-
loaded myocytes). This indicated that bona-fide myocyte and fibroblast 
populations were being isolated and maintained in our aggregates. 
Aggregates were imaged live on a confocal microscope 24, 48, and 72 hours after 
fibroblast seeding. Aggregates of mixed cells showed no changes in patterns of 
cell organization (Fig. 2-4A). Though previous studies of similar aggregates 
reported that cells separated by cell type [249,250], this phenomenon did not occur 
in our hands. In multi-layer aggregates of myocytes and fibroblasts, fibroblasts 
migrated toward the center of the aggregates over time, pushing the myocytes 
outward (Fig. 2-4B). 
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Treatment with a peptide mimetic of connexin43 altered fibroblast migration and 
patterns of cellular cohesion, which was not correlated with adhesion molecule 
changes 
Previous data from our lab shows that treatment with a peptide mimetic of Cx43 
can improve cardiac function in an experimental model of MI [104]. To better 
understand the mechanism by which this happens, we treated myocyte-fibroblast 
aggregates in the IBZ culture model with this peptide (αCT1). Analysis of fibroblast 
migration in these aggregates showed that this effect could be measured, and 
occurred to a greater degree in fibroblasts treated with αCT1, as the average 
distance of fibroblasts from the center of the aggregate decreased significantly 
over time (Fig. 2-4C, p < 0.05). 
Since cellular organization changes in the IBZ, we examined the in vitro model for 
patterns of cellular cohesion. In CTRL aggregates, individual myocytes appeared 
to be separated by fibroblasts (Fig. 2-4D). By contrast, in aggregates treated with 
αCT1, myocytes and fibroblasts tended to remain more clustered together in 
cohesive groups. To measure this, the number of myocyte clusters in each 
aggregate was counted at the 72 hour time point, as this was the stage at which 
changes in cell organization were stabilized. αCT1-treated aggregates had 
significantly fewer clusters of myocytes, indicating that myocytes were more 
clustered together in treated aggregates compared to controls (Fig. 2-4E, p < 0.05). 
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Since adhesion molecules are known to influence patterns of cell sorting [39,40], 
we examined levels of adhesion molecules using a pan-cadherin antibody that 
cross reacts with all known members of the cadherin family (including N-, E-, and 
P-cadherin) in fixed sections of the aggregates at 72 hours. Labeling for proteins 
in whole mount aggregates was not feasible due to limitations of light penetrance 
and working distance of objectives. In fixed sections of aggregates, no significant 
differences in pan-cadherin levels were found between αCT1-treated aggregates 
and controls (Fig. 2-6; p = 0.404 and p = 0.494). When we investigated these 
phenomena further, it was found that these sorting effects were strongly correlated 
to differences in levels of Cx43 in heterocellular interactions between treatment 
and control (described and discussed in detail in Chapter 4). Though classical 
adhesion molecule adhesive forces are much stronger than connexins, in the 
absence of adhesion molecules, cells are known to sort based on connexin 
proteins [41]. 
 
Extensive analysis of other model parameters revealed important markers 
Other system parameters were measured that may indicate drug mechanism. All 
of these changes were measured as a difference between 24 and 72 hours, though 
none was significant by time or treatment. These include aggregate size and cell 
number, which showed decreases of ~25% and ~20%, respectively (data not 
shown). This slight reduction in aggregate size observed in response to αCT1 is 
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likely accounted for by compaction of the cells within the aggregates. Though 
fibroblasts moved toward the aggregate center (measured as cell distance from 
the aggregate center) by ~30% over time and showed a significant treatment 
effect, myocytes did not show this same change (data not shown). Another 
parameter measured was ratio of red to green cells. This parameter was neither 
significant by time, nor did it show a treatment effect (data not shown). These 
results indicate that the Cx43 mimetic peptide likely did not significantly affect cell 
proliferation or death rates. Since these are all parameters that can be measured 
in live cell aggregates, these determinations can be made quickly from this model. 
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Figure 2-6. Cadherin levels were not affected by treatment with αCT1. 
Immunolabeling for pan-cadherin (A) and subsequent quantification (B) indicated no 
treatment effect on levels of these adhesion molecules whether normalized to aggregate 
size (left) or cell number (right). Scale = 50 µm. 
Figure 2-5. Verification of cell type by immunolabeling. Fibroblasts (green) are loaded 
with CellTracker Green dye and myocytes (red) are loaded with CellTracker Orange dye. 
A) Vimentin labeling (blue) for fibroblasts overlaps with green signal. B) MF20 labeling 
(blue) for myocytes overlaps with red signal. Scale = 50 µm. 
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2.4   Discussion 
Using non-adhesive, optically transparent micromolds, we have developed a 
model of the IBZ that incorporates myocytes and fibroblasts – i.e., the dominant 
cellular constituents of this pathogenic tissue in vivo. The micromolds used allowed 
generation of up to 96 nearly identical cell aggregates.  Larger formats would also 
be feasible in theory, permitting more aggregates to be made through a single cell 
seeding. The sizes of aggregates optimized in this model were within the diffusion 
limit of oxygen in tissues, which would prevent the center of the aggregates from 
becoming necrotic. Sequential seeding of myocytes and fibroblasts allowed the 
formation of a two-layered aggregate, which could be imaged live over several 
days to examine the changes in patterns of cell organization. Fibroblasts migrated 
to the center of heterocellular aggregates over time, forming a more or less 
coherent core of cells and pushing the myocytes outward. This effect occurred 
regardless of treatment, though treatment with αCT1 increased the fibroblast 
migration to a greater degree. Myocytes were also found to be more clustered 
together in αCT1-treated aggregates than controls, suggesting a cellular cohesive-
promoting effect of the peptide. Immunolabeling on fixed sections of aggregates 
was performed, as whole mount immunolabeling did not enable visualization of 
desired proteins due to physical limits. Similar levels of cadherin immunolabeling 
were observed in both αCT1-treated aggregates and controls, so it appeared that 
the cell sorting and clustering effects were likely not cadherin-based. Though a 
number of other parameters were measured in this model, none of them showed 
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statistically significant time or treatment effects. However, the ability to measure 
these parameters may prove important in future evaluation of novel drug 
compounds. 
Cx43-ZO-1 interaction has been implicated in cardiac disease as reorganization of 
Cx43 is frequently associated with arrhythmias in the heart. Many studies of heart 
failure in animal models and humans have shown that Cx43-ZO-1 co-localization 
is altered and Cx43 expression is reduced [79,83,251]. αCT1, a Cx43 mimetic 
peptide that inhibits Cx43-ZO-1 interaction, increases GJ plaque size and 
decreases association of Cx43 with ZO-1 at the plaque border [77]. Application of 
αCT1 to cardiac injury may, therefore, beneficially alter Cx43-ZO-1 interaction and 
reduce arrhythmogenesis. Indeed, it was found that when applied to a murine cryo-
injury model of infarction, this peptide improved several metrics of cardiac 
physiological function [104,230].  
The mechanism by which altered cell organization contributes to arrhythmias in 
the border zone is not fully understood, though these studies revealed that 
application of this peptide can affect cell organization. These changes are in 
parallel with the changes seen in the IBZ of our cryo-injury model of infarction, 
where myocytes in the IBZ were more clustered together and appeared to be 
separated by fewer fibroblasts in αCT1-treated hearts than in controls (Chapter 1). 
Changes in cellular cohesiveness in this study were not found to be based on 
cadherin effects, though it would be pertinent to further test the effect of cadherin-
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based sorting through knockdown experiments or using anti-cadherin antibodies 
in the generation of these aggregates. We did find changes in Cx43 in 
heterocellular interactions in treated aggregates versus controls that may account 
for the cell sorting effect seen here (Chapter 4). Further investigation may reveal 
a mechanism by which this peptide can therapeutically alter cell organization in the 
IBZ in vivo to reduce arrhythmia incidence [234]. 
In the IBZ model, αCT1 increased migration of fibroblasts in the 3D aggregates. 
This resembles a response previously seen in 2D scratch wound assays of 
fibroblasts in our lab, in which cells treated with αCT1 showed a significant positive 
dose-dependent migration response in a 24 hour assay. This effect was 
reproduced in our 3D heterocellular model in the presence of myocytes. 
While our purpose in this study was to generate a model of the IBZ, a similar 
heterocellular model could be used to study other cardiac fibrotic diseases. For 
example, instead of the focal scar that forms in the ischemic area in MI, diffuse 
interstitial fibrosis develops in the pressure overloaded heart, with no drastic 
change in cell organization. The mixed-cell aggregates where a 1:1 suspension of 
myocytes and fibroblasts is seeded in the micromolds would more accurately 
represent the cellular tissue structure of the pressure overloaded heart. 
Additionally, ischemia could be simulated in either of these models by culturing 
aggregates in a low-oxygen environment. 
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3D in vitro models have been frequently used to study tissue processes and drug 
development. Multicellular spheroids have been utilized to study tumor 
microenvironment and growth since 1988 [252,253], and have been used more 
recently to bridge the gap between in vitro and pre-clinical models in development 
of cancer therapeutics [254]. A cardiac spheroid model has also been developed 
in Mende’s lab [255]. While our work has been validated by a number of their 
observations in this model, their work has focused primarily on modeling 
electrophysiological properties and calcium handling in these microtissues, and 
they do not report changes in heterocellular interactions. 
While in vitro models cannot reproduce in vivo disease processes, this model 
serves to simulate, at least in part, the changes in myocyte-fibroblast interaction 
happening in 3D at the IBZ. Additionally, other factors important to the healing and 
scar formation process may be added to this in vitro model at a relevant time point. 
For instance, inflammatory cells are recruited to the heart after MI and, along with 
the resident cells, release inflammatory molecules [153,256]. Bone marrow cells 
are often recruited to the site of injury in tissues, though the extent of this effect in 
the case of cardiac injury is debated [257–259]. These cell types – or even others 
engineered to provide a therapy – could be added to this in vitro model for analysis. 
This novel 3D in vitro model of the IBZ provides a reproducible method to study 
changes in heterocellular interactions in live cells using an optically transparent, 
porous micromolded material to form large numbers of aggregates. Using this 
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model, we have shown a treatment effect of a Cx43 mimetic peptide on fibroblast 
migration and cellular cohesion. Immunolabeling in fixed sections of these 
aggregates may be used to identify proteins relevant to these and other processes. 
Taken together, this model provides an efficient platform for efficacy testing and 
mechanistic evaluation of therapeutic compounds for treating cardiac disease 
processes.  
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CHAPTER 3:  αCT1 ALTERS CONDUCTION AND INTERCELLULAR 
COMMUNICATION, BUT NOT BONE MARROW-DERIVED CELL 
RECRUITMENT TO THE CRYO-INJURED HEART 
 
3.1   Introduction 
The changes in histoarchitecture, connexin distribution, and cell phenotypes that 
occur in the IBZ after MI alter the electrophysiological properties of this tissue 
substrate and contribute to generation of arrhythmias [160,233,260–262]. Previous 
studies demonstrate action potential slowing through the IBZ [160,233], increased 
coupling of myocytes and fibroblasts via connexin proteins [167,173], and altered 
tissue architecture with increased collagen deposition [11,140]. Fibroblasts are 
activated by injury in the myocardium and proliferate and migrate (or arrive from 
extra-cardiac sources, like the bone marrow [162–165]) into the scar. Fibroblast 
proliferation in the IBZ can separate myocytes from each other. There is a need to 
understand the interplay between these structural changes in order to develop 
targeted therapies. 
While intercellular communication of myocardial cells is well-established, as 
conduction spread through the myocardium is thought to rely on passage of ions 
through GJs [263,264], the presence and function of heterocellular coupling via 
connexins is not well understood. Heterocellular coupling is well established in 
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vitro, as cells removed from the native myocardium increase their expression of 
connexin proteins [152,155,265,266], and is increased in disease [173], as the 
phenotype of cardiac fibroblasts changes in response to injury [267–269]. The 
overall effect of this increased coupling in the context of other changes to the post-
MI environment is currently unknown. It may be that altered myocyte-fibroblast 
coupling is responsible for changes in conduction in the IBZ. However, presence 
of connexin immunolabeling used to probe heterocellular interactions in these 
studies does not necessarily imply functional GJ channels. Previous work from our 
lab has shown that treatment of cryo-injured hearts with αCT1 led to a reduced 
propensity for inducible arrhythmias and lower arrhythmia severity score [104]. 
These changes were associated with an increased tendency for Cx43 to be 
maintained at the IDs in the IBZ. Additionally, there was an increase in Cx43 that 
was phosphorylated at serine 368 in the IBZ. 
S368 phosphorylation is associated with a decrease in unitary conductance  of the 
GJ channel [58], perhaps as a protective mechanism against the spread of injury 
signal in the heart [94,175,188,270]. Somewhat paradoxically, increased pS368 
(i.e. decreased communication) in αCT1-treated hearts was associated with fewer 
arrhythmias and lower arrhythmia severity scores in our studies [104]. This 
suggests that communication is altered in the IBZ, though there is a need to better 
understand the cellular and molecular mechanism for this. 
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Cells recruited to the site of MI may also affect electrophysiological properties. 
Since the first report in 2001 [271], bone marrow derived cells (BMCs) – a recruited 
cell type – have been extensively studied for their utility in cardiac repair. Reports 
in the literature suggest a range of contribution of BMCs – which can be mobilized 
by injury signals and recruited to the site of injury – to healing of the injured heart 
[162–165]. Clinical trials of exogenously applied BMCs post-MI suggest modest 
benefit from paracrine factors [272] and exosome release [273,274] (i.e. the 
presence of the cells themselves is not required). However, there is further room 
for improvement of this type of therapy, as the BMCs could be used as a delivery 
vehicle. For example, if sufficient numbers of cells are recruited to the scar and 
IBZ, BMCs could be engineered to express increased levels of connexins (they 
already express some [275]) and ion channels in order to improve 
electrophysiological properties of the IBZ and scar. 
To assess whether αCT1 alters conduction in the IBZ and can alter GJIC, we 
studied the effect of the peptide on conduction velocity through the IBZ in cryo-
injured hearts and examined direct intercellular communication in an in vitro 
parachute communication assay. To determine the contribution of endogenous 
recruited BMCs to the IBZ and scar, we transduced the femoral cavity of mice after 
delivery of a cardiac cryo-injury to assess the efficiency with which labeled cells 
were recruited to the site of injury. 
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3.2   Methods 
Animal care and use: All animal research was conducted under the guidance of 
the Institutional Animal Care and Use Committee at Virginia Polytechnic Institute 
and State University and conform to the NIH Guide for the Care and Usage of 
Laboratory Animals. 
Cryo-injury: CD-1 Mice (12-24 weeks old, Charles River Labs) were anesthetized 
by exposure to 5% isoflurane in oxygen. The mice were placed in supine position 
and the trachea intubated, under direct visualization, with a 22-gauge 
angiocatheter over a blunt introducer. The mice were ventilated with 2% isoflurane 
in oxygen at a tidal volume of 250 µl and 150 cycles/minute. Mice were given 
buprenorphine pre-operatively (50-100 mg/kg SC). Maintaining sterile technique, 
a left thoracotomy was performed at the fourth intercostal space, using a (MZ75, 
Leica) dissecting scope. All muscles overlying the intercostal space were dissected 
free and retracted with a home-built retractor. After opening the thorax, the 
pericardial sack was opened and the left lung was reflected to allow a clear view 
of the heart. The left ventricular free wall was cryo-injured by direct exposure to a 
prechilled (10 sec) 3mm flat-tip circular probe of a cryo-gun for 5 seconds (CRY-
AC-3, Brymill). Treatments were delivered to the surface of the heart in 
methylcellulose patches containing 100 µM αCT1 or reverse peptide, or water for 
vehicle control. After cryo-injury, the incision was closed in layers using 6-0 
Prolene sutures (Ethicon) and the skin sealed with Gluture skin glue (Abbott). Mice 
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remained on the ventilator receiving oxygen until they began spontaneous 
respiration. After surgery, the mice were given carprofen (2-5 mg/kg SC) for 
analgesia and placed on a warming blanket until recovery from anesthesia was 
complete. Mice were then returned to their cages where they received treatment 
with buprenorphine every 12 hours for 48 hours and carprofen every 24 hours for 
48 hours. Animals were sacrificed 1 week after surgery, hearts collected, and fresh 
frozen in OCT. 
Lentiviral transduction of bone marrow cells: After cryo-injury was performed, a 
small incision was made in the skin over the mouse hindlimb patella. The knee 
was placed in flexion and a 27 gauge needle was used to bore a hole through the 
end of the femur into the bone marrow cavity. A 30 ga needle was used to inject 
20 µL of lentiviral TurboGFP (Penn State Vector Core). 
Langendorff perfusion: 8 weeks after cryo-injury and bone marrow transduction, 
mice were anesthetized via isoflurane inhalation and cervically dislocated. The 
hearts were quickly excised, the aorta cannulated, and retrogradely perfused. 
Hearts were perfused with solutions (pH 7.4) described in Table 3-1 at a flow rate 
of 1 to 1.5 ml/min maintaining the perfusion pressure at approximately 65 mmHg. 
The temperatures of the perfusate and the bath were maintained at 37 °C. 
Electrophysiology was quantified in hearts perfused with either low sodium and 
high potassium, or high sodium and low potassium as described in Table 3-1 (5 
CTRL and 4 αCT1-treated animals). 
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Optical mapping: Hearts were optically mapped with the voltage-sensitive dye, Di-
4-ANEPPS, perfused at a concentration of 4 µM for approximately 5 min. Motion 
was arrested with the electromechanical uncoupler, 2,3-butanedione monoxime, 
or blebbistatin (BDM) at the concentrations listed in Table 3-1. Hearts were 
stabilized against the front glass of the bath by applying slight pressure to the back 
of the heart. The center of the anterior ventricular surface was paced with a 
unipolar silver wire with a reference electrode at the back of the bath. Hearts were 
stimulated at ~1V for 1 ms at a burst cycle length of 150 ms. Excitation light from 
a halogen light source (MHAB-150W, Moritex Corporation) was filtered by a 510-
nm filter (Brightline Fluorescence Filter) before it reached the heart. The emitted 
light was filtered by a 610-nm filter (610FG01-50(T257), Andover Corporation) 
before it was recorded using aMiCam Ultima CMOS L-camera at a sampling rate 
of 1000 frames/s. The camera captured optical signals from an area of 1 cm2 in a 
100×100 pixel array with an interpixel resolution of 0.1 mm. 
Activation times were assigned to the maximum rate of rise of an action potential 
as previously reported [276] and conduction velocity was calculated using the 
Bayly et al. algorithm [277]. In short, activation time was determined from the 
maximum rate of optical action potential rise at each pixel, and a parabolic surface 
was fit to activation times in order to determine a conduction velocity vector at each 
pixel. Activation delay was calculated at multiple points along a line drawn through 
the pacing site and the scar, normal to the IBZ. 
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Primary cell isolation: Primary cardiac neonatal rat ventricular myocytes and 
neonatal rat ventricular fibroblasts (NRVFs) were isolated from 2-day neonatal rats 
by digestion in trypsin (Worthington), Pancreatin (Fisher), Collagenase II 
(Worthington), and elastase (Fisher) in HBSS (Hyclone). Cells were separated on 
a Percoll (GE Healthcare) gradient, and washed. Fibroblasts were seeded and 
cultured in DMEM (Hyclone or Gibco) supplemented with FBS (Hyclone), 10U/ml 
penicillin and 10µg/ml streptomycin (Hyclone), and 2mM L-alanyl-L-glutamine 
(Fisher) and maintained in an incubator at 37°C, 5% CO2. Myocytes were seeded 
in myocyte complete medium (M199 supplemented with 0.16% glucose (Sigma), 
1x MEM vitamins (Gibco), 1x NEAA (Gibco), 1x MEM Amino acids (Gibco), 10 
U/ml penicillin and 10 µg/ml streptomycin (Hyclone), 10% horse serum (Gibco), 
and 5% FBS (Hyclone)).  
Density gradient centrifugation: Due to their differences in densities, myocytes and 
fibroblasts can be separated by density gradient centrifugation. As such, Percoll 
(GE Healthcare) was used to generate a two-layer gradient in which a layer of 
Percoll of 1.060 g/mL density was underlaid with a layer of Percoll of 1.080 g/mL 
density. Cells from no more than 4 digested rat pup hearts were suspended in 1x 
ADS solution, laid onto the top of the gradient, and centrifuged at 3000 rpm for 30 
minutes with no brake. Myocytes sink to the bottom density interface and 
fibroblasts remain at the top interface. Cells are then collected and washed in 
complete medium for the respective cell type. 
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Parachute assay: Myocyte or fibroblast acceptor cells were seeded and grown to 
confluence on 2-well glass chamber slides coated with gelatin (myocytes) or poly-
L-lysine (fibroblasts). Donor fibroblasts were grown in 6-well plates. Donor and 
acceptor cells were treated with 100 µM αCT1 or reverse control peptide or HBSS 
vehicle control for 48 hours with daily media changes. At the time of parachute, 
donor cells were loaded with 5 µM calcein AM (Life Technologies) and 2.5 µM 
CellTracker Orange (CMRA) (Life Technologies) in OptiMEM (Gibco) for 45 
minutes at 37°C. Donor fibroblasts were washed in PBS, trypsinized, and 
parachuted in complete medium with 100 µM treatments. Transfer was allowed to 
progress for 4 hours at 37°C and cells were mounted in OptiMEM and imaged on 
an Olympus BX61VS slide scanner. Only transferring cells were counted. 
Statistics: 2-way ANOVA was performed on optical mapping data. Comparisons 
between treatment groups in a parachute assay was performed with a mixed 
model design. After it was determined that interaction effects could be eliminated, 
experiments were split by cell type for analysis. ANOVA was performed with Least 
Significant Difference (LSD) for inter-group comparisons. 
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3.3   Results 
αCT1 reduces conduction delay at the IBZ 
Cryo-injured hearts were optically mapped 8 weeks after injury with the voltage 
sensitive dye Di-4-ANEPPs. Extracellular ion concentration was varied during the 
mapping procedure by using perfusates of different composition (Table 3-1). In 
control hearts, optical maps showed a crowding of isochrone lines at the 
approximate location of the IBZ with low sodium and high potassium, but not with 
high sodium and low potassium (Fig. 3-1A). αCT1-treated hearts showed relatively 
uniform conduction through the IBZ and did not exhibit this conduction delay in low 
sodium and high potassium (Fig. 3-1A). Conduction delay through the IBZ was 
calculated at points along a line through the pacing site and normal to the IBZ. In 
control hearts, a low sodium concentration and high potassium concentration 
unmasked a significant delay that was not seen when mapped with a high sodium 
concentration and low potassium concentration (Fig. 3-1B; p = 0.002). In hearts 
treated with αCT1, neither solution altered conduction delay at the IBZ with respect 
to the other (Fig 3-1B; p = 0.176). While αCT1-treated hearts and CTRL hearts 
were not directly compared, it appears that αCT1 protected against non-uniform 
conduction slowing in the IBZ in the presence of varying extracellular ion 
concentration while controls did not. 
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Table 3-1. Perfusate composition for optical mapping (in mM). 
 Solution 1 Solution 2 
NaCl 130 118.3 
NaHCO3 24 29 
NaH2PO4 1.2  
Total [Na+] 155.2 147.3 
KCl 4 4.7 
K2HPO4  1.4 
Total [K+] 4 6.1 
MgCl2 1  
MgSO4  1 
Glucose 5.6 10 
CaCl2 1.8 3.4 
BDM 15 10 
Figure 3-1. αCT1 reduces conduction delay at the IBZ. A) Optical maps of cryo-injured 
hearts in either high sodium and low potassium (left) or low sodium and high potassium 
(right). An asterisk marks the approximate IBZ area. B) Low sodium and high potassium 
solution unmasks a significant conduction delay at the IBZ in controls that is not seen in 
αCT1-treated hearts. 
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Figure 3-2. Parachute assay of gap junctional intercellular communication (GJIC). 
A) Communication was assessed in myocyte-fibroblast interactions and fibroblast-
fibroblast interactions. Arrowheads show calcein (green) and CellTracker (red) parachuted 
cells. White arrows show acceptor cells that have received calcein (green) from the 
parachuted cells. B) αCT1 decreased communication between myocytes and fibroblasts 
and in fibroblast homocellular connections compared to reverse and vehicle controls. 
Scale = 250 µm. 
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αCT1 decreases GJIC between homocellular and heterocellular contacts 
Since we saw alterations in conduction at the IBZ with varying ion concentrations 
in treated hearts versus controls, and previous data (Chapter 1) showed that 
treating cryo-injured hearts with αCT1 led to changes in patterns of cellular 
organization in the IBZ, we assessed GJIC in a parachute communication assay 
to examine myocyte-fibroblast communication and fibroblast-fibroblast 
communication. To perform the parachute assay, an acceptor cell layer of NRVMs 
was plated near confluence in glass chamber slides and allowed to form mature 
GJs over several days in culture, as evidenced by synchronous beating of cells. 
For 48 hours before the assay was performed, both donor and acceptor cells were 
treated with 100 µM αCT1 or reverse or vehicle control with daily medium changes. 
Donor cells were then loaded with the GJ-permeable dye Calcein green and the 
GJ-impermeable dye CellTracker Orange (CMFDA) and parachuted at a 1:15 
dilution on top of the confluent acceptor layer of NRVMs. The parachuted NRVFs 
settled and adhered to the NRVMs. If functional GJs were formed between the 
donor and acceptor cells, Calcein green, but not CellTracker Orange, was 
transferred to the acceptor cells (Fig 3-2). As a measure of communication, the 
acceptor cells to which dye was transferred were counted. All non-transferring cells 
were excluded from the analysis. 
Surprisingly, it appeared that αCT1 treatment of cultures led to a decrease in GJIC 
in heterocellular parachute assays (Fig 3-2). This suggests that αCT1 treatment  
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Previous data from the Gourdie lab showed that αCT1 treatment of hearts led to 
an increase in pS368 and this effect was maintained in vivo for several hours after 
application of the peptide [104]. Phosphorylation of Cx43 at serine 368 is known 
to be associated with a decrease in unitary conductance of the GJ channel. So it 
may be that the peptide is inducing phosphorylation of Cx43 in myocyte-fibroblast 
connections and in fibroblast-fibroblast connections, leading to a decrease in GJIC. 
 
Contribution of recruited bone marrow cells to healing after cryo-injury 
In order to investigate the effect of αCT1-treatment on efficiency of recruitment of 
BMCs, and subsequently examine whether there is a difference in GJ coupling in 
the heart, we labeled the femoral bone marrow cavity of cryo-injured mice. Mice 
were subjected to cryo-injury, then lentiviral Turbo-GFP was injected into the 
femoral bone marrow cavity to label the cells. Theoretically, any transduced cell in 
the bone marrow cavity that was recruited outside of the bone marrow would 
express GFP in its new location. Mice were allowed to recover for 8 weeks before 
the hearts were excised and examined. 
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Figure 3-3. Recruitment of bone marrow derived cells to the healing infarct. A&B) 
Little evidence of GFP-positive cells were seen in the scar area. C) GFP-positive cells 
were found on the apex of the heart. D) Adjacent to the IBZ, several brick-shaped weakly-
GFP positive cells were found. 
86 
 
For gross examination of recruited BMCs, hearts were cannulated and placed on 
gravity perfusion and imaged on a confocal microscope with motion arrested by 
BDM. Figure 3-3 depicts several scans taken from different hearts. While we did 
find a few green cells on the epicardial surface of cryo-injured hearts (Fig. 3-
3C&D), we could not find clear GFP signal in the IBZ of these hearts (Fig. 3-3B). 
In the apex of the heart, there appeared to be several GFP positive cells, though 
this area was not injured (Fig. 3-3C). Additionally, there was little evidence for 
GFP-positive cells anywhere in the cryo-injury scar (Fig. 3-3A). Interestingly, we 
did find some brick-shaped cells (possibly myocytes) that were weakly GFP-
positive in the myocardium adjacent to the IBZ (Fig. 3-3D), though the significance  
of these cells is unknown. Overall it appeared that recruitment of GFP-positive 
BMCs to the site of cryo-injury was low. 
 
3.4   Discussion 
These studies describe data elucidating the cellular determinants of reduced 
arrhythmogenicity in the IBZ of αCT1-treated hearts. αCT1 was shown to reduce 
conduction delay in the IBZ in the context of altered extracellular ion concentration, 
and decrease myocyte-fibroblast heterocellular communication and fibroblast 
homocellular communication, though it appeared to have no effect on BMCs 
recruited to the cryo-injury. 
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αCT1 protected against conduction delay in the IBZ in varying extracellular ion 
concentrations, while control hearts showed a significant delay in conduction 
through the IBZ. These results indicate that αCT1 may be contributing to the 
generation of a more uniform electrophysiological substrate in the IBZ. Previous 
data from the cryo-injury model in our lab show altered patterns of cellular 
localization in the IBZ of αCT1-treated hearts compared to controls (Chapter 1). In 
the IBZ of control hearts, collagen deposition and fibroblasts separated individual 
myocytes from each other, interrupting patterns of electrical coupling. In contrast, 
myocytes in the IBZ of αCT1-treated hearts were more clustered together in 
cohesive groups and showed less evidence of intercalated non-myocytes. αCT1 
treatment also led to a higher percentage of myocytes to non-myocytes in the IBZ. 
This correlates with experimental modeling data that shows that increasing 
fibroblasts in the IBZ can exacerbate arrhythmia propensity, though this study did 
not incorporate effects of cellular organization [260]. Similarly, a report by Miragoli 
et al. found that ectopic activity in cultured strands of ventricular myocytes was 
increased with increasing fibroblast concentrations [278]. 
Cardiac myocytes and fibroblasts have vastly different electrophysiological 
properties, and alterations in coupling between these cell types could contribute to 
arrhythmia generation. Fibroblasts – a non-excitable cell type – have a more 
depolarized resting membrane potential compared to myocytes [21,242,279], and 
higher membrane resistance [21,279,280] and capacitance [281,282]. In vitro and 
in silico studies suggest that a fibroblast may act as a current sink when coupled 
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to a myocyte [21,283], potentially giving rise to arrhythmias [284]. Studies in the 
sheep heart have shown an increase in structural coupling by connexins in 
heterocellular interactions in the IBZ [173], suggesting the possibility of increased 
myocyte-fibroblast functional coupling in the IBZ, though the only functional in vivo 
studies on heterocellular coupling were done in the sinoatrial node of healthy rabbit 
heart [285].  Previous studies from our lab on the αCT1 peptide suggested an 
increase in GJIC and a decrease in hemichannel-mediated communication [57]. 
By contrast, in our dye coupling studies, αCT1 reduced GJIC between myocytes 
and fibroblasts, and among fibroblasts. Our previous data on studies of the heart 
demonstrate the ability for αCT1 to increase pS368 [104,105], which decreases 
communication. While this result was unexpected, reduced communication in 
heterocellular contacts (which are rare in healthy myocardium [117,122]) may be 
accountable for more uniform conduction in the IBZ. For example, reduced 
electrotonic coupling between myocytes and fibroblasts (in which fibroblasts could 
act as a current sink) would lead to more normal electrophysiological properties of 
the IBZ. Interestingly, we found a large increase in the amount of Cx43 in 
heterocellular interactions between myocytes and fibroblasts in our in vitro model, 
though, in light of the dye coupling data presented here, it would suggest a 
mechanical role for Cx43 in those interactions (see Chapter 4). 
Injection of lentiviral Turbo-GFP into the femoral cavity of cryo-injured mouse 
yielded few GFP-positive cells on the surface of the heart 8 weeks after injury. 
BMCs are thought to be mobilized by injury signals, though they need to 
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subsequently home to and engraft in the injured tissue [162–165]. This process is 
not always efficient, though strategies using heterospecific homing antibodies are 
being developed to improve this, and have been shown to increase engraftment of 
intravascularly injected cells in the heart [286]. These antibodies are engineered 
to be specific for the antigens of two cell types. In this case, they first bind to the 
target cardiac cells, and then to specific antigens on the injected cells. This 
strategy holds promise with both administered cell types, as well as those recruited 
to the site of injury. 
It is also possible that lentiviral injection into the bone marrow cavity of cryo-injured 
mice did not efficiently label cells in that compartment. The percentage of BMCs 
that are recruited to injured tissue is low, and this would be further challenged by 
a low labeling efficiency in the bone marrow cavity. While some reports suggest 
the ability of BMCs to differentiate into a myocyte-like phenotype [271], this seems 
to be a rare event, if possible at all [287,288]. It is more likely that these GFP-
positive brick shaped cells arose as a cell-fusion event [289]. Overall, our attempt 
to study the contribution of BMCs to the cardiac cryo-injury did not yield conclusive 
results. Other reporter systems exist that may provide more robust methods to 
study this effect. These include bone marrow chimeras in which animals are 
irradiated to kill native bone marrow, followed by subsequent transplantation of 
reporter bone marrow cells in the bone marrow cavity [257,290] or a transgenic 
reporter model. Robust reporter models of monocytes [291] and hematopoetic 
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stem cells [292] have been developed, though tracking bone marrow 
mesenchymal cells is challenged by lack of a specific marker for this cell type [293]. 
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CHAPTER 4:  αCT1 ALTERS MYOCYTE-FIBROBLAST INTERACTIONS VIA 
CONNEXIN43 AND CONNEXIN43 GAP JUNCTION PLAQUE SUBDOMAIN 
ORGANIZATION 
 
4.1   Introduction 
MI induces several changes in heterocellular interactions in the IBZ and scar. One 
of the best known is the reorganization of Cx43 to the lateral borders of myocytes 
in the IBZ, which is thought to contribute to arrhythmia generation. While the 
traditional role of connexin proteins is in intercellular communication, there are 
several studies suggesting their importance in cell adhesion [36–38]. Cadherins 
are known to be responsible for cell sorting as per the differential adhesion 
hypothesis [39] and subsequent substantiating research [40]. Even though 
cadherin adhesion forces are stronger than that of connexins, connexin-based cell 
sorting effects have also been demonstrated, and these effects seem to have a 
similar influence as cadherin-based effects [41]. Work from Chapter 2 suggests 
that this could be the case in our models with αCT1, as altered patterns of cell 
organization were seen in aggregates with no detectable treatment-induced 
differences in cadherin levels. 
In EM and immunolabeling studies of the heart, Cx43 can be found in interactions 
between myocytes and fibroblasts [117,122]. An immunolabeling study in the 
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rabbit ventricle indicated that as much as 3.2% of Cx43 was localized to the 
interface of these heterocellular interactions [117], and that this percentage 
increased in the IBZ after MI in the sheep [173]. Though one study in canine 
infarction found a heterogeneous decrease in Cx43 in the border zone and no 
evidence of heterocellular coupling [294]. However, the ability of myocytes and 
fibroblasts to couple via GJs is supported by the increased expression of connexin 
proteins in activated fibroblasts, which are present in the IBZ [167,172,173]. There 
is further work to be done to understand the presence and distribution of myocyte-
fibroblast coupling via Cx43 in both healthy and diseased myocardium. 
Cx43 phosphorylation at serine 368 results in a decrease in unitary conductance 
of the GJ channel [58]. In the post-MI heart, Cx43 pS368 is associated with the 
Cx43 that is maintained at the ID, both in our studies and those of others [104,295]. 
Other reports have suggested that Cx43 phosphorylation is a protective 
mechanism against injury spread in the heart [94,175,188,270]. 
Some of the first studies from our lab examining inhibition of the Cx43-ZO-1 
interaction by αCT1 peptide showed that this led to an increase in GJ plaque size 
[77]. Subsequent work confirmed that Cx43-ZO-1 interaction regulated GJ size by 
controlling the rate at which hemichannels waiting in the perinexus flowed into the 
GJ plaque [57]. Hemichannels are known to be added to the GJ at the periphery 
of the plaque [26,52,56], and progressive phosphorylation seems to be associated 
with their incorporation into the plaque [90]. However, some reports suggest the 
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possibility that Cx43 may be phosphorylated to some extent before it reaches the 
membrane [96,97]. This may affect the GJ plaque substructure, though to date, 
there are no reports on GJ plaque substructure with respect to connexin 
phosphorylation. Immuno-confocal images currently provide the best detail 
available on the localization of proteins within the GJ. However, the majority of 
these studies display findings that suggest co-localization of proteins. Super 
resolution microscopy techniques are becoming more readily available and shed 
some light onto the localization of proteins in the GJ plaque at the single molecule 
level [120]. 
The previous chapter examined the presence and function of communication in 
the cryo-injured hearts. Here, we aim to understand whether and how myocytes 
and fibroblasts are coupled via Cx43 GJs. To examine the presence and extent of 
myocyte-fibroblast coupling via GJs and the differences in structure induced in the 
Cx43 GJ plaque, we use an approach based on immuno-confocal and immuno-
super resolution techniques. Importantly, for the development of a robust in vitro 
IBZ model, the drug responses observed in vitro are validated against the 
physiological responses seen in the disease model in vivo. 
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4.2   Methods 
Cell isolation and labeling: Primary cardiac neonatal rat ventricular myocytes and 
neonatal rat ventricular fibroblasts (NRVFs) were isolated from 2-day neonatal rats 
by digestion in trypsin (Worthington), Pancreatin (Fisher), Collagenase II 
(Worthington), and elastase (Fisher) in HBSS (Hyclone). Cells were separated on 
a Percoll (GE Healthcare) gradient, and washed. Fibroblasts were seeded and 
cultured in DMEM (Hyclone or Gibco) supplemented with FBS (Hyclone), 10U/ml 
penicillin and 10µg/ml streptomycin (Hyclone), and 2mM L-alanyl-L-glutamine 
(Fisher) and maintained in an incubator at 37°C, 5% CO2. Myocytes were labeled 
immediately in 2.5 µM CellTracker Orange (CMRA) (Life Technologies) in 
OptiMEM (Gibco) for 30 minutes and washed in myocyte complete medium (M199 
supplemented with 0.16% glucose (Sigma), 1x MEM vitamins (Gibco), 1x NEAA 
(Gibco), 1x MEM Amino acids (Gibco), 10U/ml penicillin and 10µg/ml streptomycin 
(Hyclone), 10% horse serum (Gibco), and 5% FBS (Hyclone)). Myocytes were 
seeded at 30,000 cells per mold and allowed to aggregate for 48 hours. Before 
seeding, fibroblasts were washed in PBS, labeled with 2.5 µM CellTracker Green 
(CMFDA) in OptiMEM (Gibco) for 30 minutes and washed in fibroblast medium. 
Fibroblasts were added at 48 hours at 30,000 cells per mold. Culture medium 
(including treatments) was changed every 24 hours. Aggregates were treated with 
100 µM αCT1, reverse control peptide, or vehicle control. 
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Cx43 mimetic peptides: Two peptides (American Peptide) were generated: αCT1 
and a reverse sequence control peptide (REV). These peptides contain an N-
terminal biotin tag followed by the 16-amino acid antennapedia internalization 
vector (RQPKIWFPNRRKPWKK). Linked to the C-terminal lysine (K) of the 
antennapedia sequence is either the C-terminal 9-amino acids of Cx43 
(RPRPDDLEI; αCT1) or the Cx43 C-terminal 9-amino acids in reverse 
(IELDDPRPR; REV). 
Animal care and use: All animal research was conducted under the guidance of 
the Institutional Animal Care and Use Committee of Virginia Polytechnic and State 
University and conforms to the NIH Guide for the Care and Usage of Laboratory 
Animals.  
Cryo-injury: CD-1 Mice (12-24 weeks old, Charles River Labs) were anesthetized 
by exposure to 5% isoflurane in oxygen. The mice were placed in supine position 
and the trachea intubated, under direct visualization, with a 22-gauge 
angiocatheter over a blunt introducer. The mice were ventilated with 2% isoflurane 
in oxygen at a tidal volume of 250 µl and 150 cycles/minute. Mice were given 
buprenorphine pre-operatively (50-100 mg/kg SC). Maintaining sterile technique, 
a left thoracotomy was performed at the fourth intercostal space, using a Leica 
MZ75 dissecting scope. All muscles overlying the intercostal space were dissected 
free and retracted with a home-built retractor. After opening the thorax, the 
pericardial sack was opened and the left lung was reflected to allow a clear view 
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of the heart. The left ventricular free wall was cryo-injured by direct exposure to a 
prechilled (10 sec) 3mm flat-tip circular probe of a cryo-gun for 5 seconds (CRY-
AC-3, Brymill). Treatments were delivered to the surface of the heart in 
methylcellulose patches containing 100 µM αCT1 or reverse peptide, or water for 
vehicle control. After cryo-injury, the incision was closed in layers using 6-0 
Prolene sutures (Ethicon) and the skin sealed with Gluture skin glue (Abbott). Mice 
remained on the ventilator receiving oxygen until they began spontaneous 
respiration. After surgery, the mice were given carprofen (2-5 mg/kg SC) for 
analgesia and placed on a warming blanket until recovery from anesthesia was 
complete. Mice were then returned to their cages where they received treatment 
with buprenorphine every 12 hours for 48 hours and carprofen every 24 hours for 
48 hours. Animals were sacrificed 1 week after surgery, hearts collected, and fresh 
frozen in OCT. 
Immunolabeling: At 72 hours, aggregates were fixed in 4% paraformaldehyde for 
10 minutes at room temperature, washed, and embedded in OCT for frozen 
sectioning. Aggregates were cut in thin sections of 5-10 µm and allowed to dry for 
30 minutes. Cryo-injured hearts were cut in thin sections of 10 µm. Sections of 
aggregates or hearts were blocked with 1% BSA (Fisher Scientific), 0.1% Triton-
X-100 (Fisher Scientific) in PBS. Cells were labeled for Cx43 (1:2000 Sigma, 1:100 
Abcam, or 1:100 Chemicon), Cx43 pS368 (1:200 Cell Signaling), or 1:1000 pan-
cadherin (Sigma). Hearts were counterstained with vimentin (Millipore) (1:1000) 
and MF20 (DSHB) (1:100). Labeling was viewed with AlexaFluor secondary 
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antibodies and stained with Hoechst 33342 (Sigma; nuclear labeling). For gSTED 
immunolabeling, proteins were visualized with goat anti-rabbit Chromeo 505 
(1:100) and anti-mouse biotin (1:200) followed by streptavidin- conjugated Horizon 
V500 (1:100) secondary antibodies. For single molecule localization, cells and 
tissue were fixed in 4% paraformaldehyde, reduced in 0.1 M glycine, permeabilized 
in PBS with 0.2% Triton-X-100, and blocked in goat serum. Samples were labeled 
for Cx43 (Chemicon) and Cx43 pS368 overnight at 4°C, washed and visualized 
with AlexaFluor 647 (1:4000) and Cy3b (1:50). 
Confocal, gSTED, and single molecule localization microscopy: For confocal, 
immunolabeled samples were imaged on a Leica SP8 LSCM with a Plan 
Apochromat 63x/1.4 NA oil immersion objective and Leica HyD hybrid detectors. 
For gSTED, immunolabeled samples were imaged on a Leica SP8 LSCM 
equipped with a gated stimulated emission depletion (gSTED) modules, a Plan 
Apochromat 63x/1.4 NA oil immersion objective, Leica HyD hybrid detectors and 
a 592-nm STED depletion laser. Fluorophores were imaged sequentially by frame. 
Two-color gSTED super-resolution images were obtained sequentially as z-stacks 
(with a step size of 10 nm) and processed using Huygens STED deconvolution 
software (Scientific Volume Imaging, Hilversum, The Netherlands). This enabled a 
maximum lateral full width at half maximum resolution of 22 nm using gSTED. For 
single molecule localization, immunolabeled samples were imaged on a Bruker 
Vutara 350 Single Molecule Localization system equipped with 555 nm and 647 
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nm lasers, and 100x objective. Two-color images were obtained sequentially as z-
stacks with a step size of 10 nm and processed with Vutara software. 
Confocal Cx43 quantification: Cx43 was quantified from images of Cx43 using the 
Sigma and Abcam antibodies for total Cx43 and an antibody for Cx43 pS368 (Cell 
Signalling). Image masks were created of the Cx43 labeling, myocytes (from 
CellTracker Orange or MF20 immunolabeling), and fibroblasts (from CellTracker 
Green, or vimentin immunolabeling) using ImageJ (NIH). Cx43 was quantified as 
fibroblast, myocyte, or fibroblast-myocyte interface. 
Statistical analyses: All data were checked for normality by Shapiro-Wilk [236–
240]. Non-normal data were transformed to normality using Box-Cox. If data could 
not be transformed to normality, non-parametric tests were used. For Cx43 area 
comparisons in myocytes, fibroblasts, and the zone of interaction of the two, 
factorial ANOVA (2 x 3) was performed with posthoc analysis by Least Significant 
Difference (LSD). Cx43 linear density was analyzed by ANOVA with posthoc 
analysis by LSD. Cx43 pS368 linear density was analyzed by Mann-Whitney U. 
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4.3   Results 
αCT1 increases myocyte-fibroblast interactions via Cx43 in an in vitro IBZ model 
As described in Chapter 2, we observed changes in cell organization in the in vitro 
IBZ model that correlated with changes in cell organization in a cryo-injury model 
of infarction (i.e. more cohesive groups of myocytes with αCT1 treatment 
compared to controls). Since we observed no differences in levels of pan-cadherin 
immunolabeling between treatments that would have suggested an effect of 
classical adhesion molecules on the cell sorting behavior, we hypothesized that 
changes in Cx43 – which also has adhesive properties – were responsible for 
changes in myocyte cohesion. The greatest change in myocyte-fibroblast 
organization was seen at 72 hours, so we looked for Cx43 at this time point. For 
analysis of Cx43 in myocyte and fibroblast compartments, image masks were used 
to separate the Cx43 immunolabeling signal into these compartments. The highest 
Cx43 particle density of total Cx43 was found in the myocyte compartment, which 
was expected, since myocytes have the greatest Cx43 expression in the heart (Fig. 
4-1A&B). A zone of myocyte-fibroblast interaction showed the next greatest 
particle density of total Cx43, and this was significantly lower than the myocyte 
compartment (Fig. 4-1B; p < 0.001). Not surprisingly, the lowest levels of Cx43 
were found in the fibroblast compartment and this was significantly lower than 
either the myocyte compartment or the myocyte-fibroblast interaction zone (Fig. 4-
1B; p < 0.001). In both the fibroblast compartment and in the myocyte-fibroblast 
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compartment, αCT1 led to a significant increase in total Cx43 particle density (Fig. 
4-1B; p < 0.001 and p < 0.05, respectively). When we measured linear Cx43 
density, where the number of Cx43 particles was normalized to the length of 
myocyte-fibroblast interaction, total Cx43 density was significantly increased in 
αCT1-treated aggregates compared to controls (Fig. 4-1B; p < 0.05). 
This analysis was repeated to examine the presence and extent of Cx43 pS368 in 
myocyte-fibroblast interactions. The highest Cx43 particle density of Cx43 pS368 
was found in the myocyte compartment, though this was not significantly greater 
than in the myocyte-fibroblast compartment (Fig. 4-1C). Not surprisingly, the 
lowest levels of Cx43 pS368 were found in the fibroblast compartment and this 
was significantly lower than either the myocyte compartment or the myocyte-
fibroblast interaction zone (Fig. 4-1C; p < 0.001). In both the myocyte compartment 
and in the myocyte-fibroblast compartment, αCT1 led to a significant increase in 
total Cx43 particle density (Fig. 4-1C; p < 0.05 and p < 0.05, respectively). There 
was no difference in Cx43 pS368 levels in the fibroblast compartment between 
αCT1-treated aggregates and controls. Linear density of Cx43 pS368 was 
significantly increased in αCT1-treated aggregates compared to controls (Fig. 4-
1C; p < 0.05). 
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Figure 4-1. Myocyte-fibroblast interactions via Cx43 are increased in the IBZ in vitro 
model. A) Cx43 (white) immunolabeling is mostly within the myocyte compartment (red 
outline), though some is present in the fibroblast compartment (green outline). There 
seems to be more punctate Cx43 in αCT1-treated aggregates. Cx43 was measured from 
immunolabeled aggregates in the myocyte compartment, the fibroblast compartment, and 
a zone of interaction between the two. B and C) Myocyte-fibroblast interactions via Cx43 
and Cx43 pS368 were significantly increased in αCT1-treated aggregates compared to 
controls. ***p < 0.001, **p < 0.01, *p < 0.05; Scale = 50 µm. 
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Overall, immunolabeling for Cx43 at the 72 hour time point showed that treatment 
with αCT1 significantly increased the amount of Cx43 in myocyte-fibroblast 
interactions compared to controls (Fig. 4-1). Interestingly, though Cx43 was 
increased in myocyte-fibroblast heterocellular interactions, phosphorylation of 
Cx43 at serine 368 was also increased. It is likely that there is a decrease in 
communication in these heterocellular contacts, as we also saw a decrease in 
heterocellular GJIC (Chapter 3). Increased clustering of myocytes was also seen 
in the aggregates at 72 hours (Chapter 2), suggesting that instead of Cx43 playing 
a role in intercellular communication, it may be serving an adhesive function in 
heterocellular interactions in the IBZ. 
 
αCT1 alters myocyte-fibroblast interactions via Cx43 in the cryo-IBZ 
As another method to validate our in vitro IBZ model and to further examine the 
changes in heterocellular interactions in the IBZ, we examined these interactions 
in the cryo-injury model at 7 days. Immunolabeling of Cx43 pS368 was undertaken 
on sections of cryo-injured mouse heart (Fig. 4-2). Confocal images demonstrated 
an increase in fibroblast infiltration into the IBZ, leading to separation of myocyte 
connections. Cx43 also appeared disordered in the IBZ compared to the regions 
remote from the injury. There was a trend toward increasing myocyte-fibroblast 
interactions via Cx43 in the IBZ. 
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Figure 4-2. Murine cryo-injury model of infarction demonstrated lateralized Cx43 in 
the IBZ. A) High-resolution tile scans of the cryo-IBZ and scar in reverse control and αCT1 
peptide-treated hearts. Scar area is largely comprised of fibroblasts (blue), which appear 
to separate myocytes (red) in the IBZ. Cx43 (green) appears decreased and lateralized in 
the IBZ. B) Fibroblasts infiltrate normal myocyte connections in the IBZ, but not in regions 
of the myocardium remote from the injury. C) There was a trend toward increased 
myocyte-fibroblast interactions via Cx43 when measured in the IBZ. 
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A novel gap junction plaque phosphorylation subdomain organization 
Previous studies from our lab have shown that αCT1 increases Cx43 pS368 in a 
PKC-dependent manner [104,105]. In order to better understand how these 
changes influence the GJ plaque structure in terms of subdomain organization, we 
undertook immuno-confocal and immuno-super-resolution imaging studies in 
cultures of NVRMs and NRVFs and in cryo-injured mouse heart tissue. Cells and 
tissues were labeled with antibodies directed against the non-phosphorylated form 
of Cx43 and against Cx43 pS368. Confocal images of myocyte-fibroblast co-
cultures demonstrated presence of small, punctate GJs between myocytes and 
fibroblasts (Fig. 4-3A). Signal from non-phosphorylated Cx43 and Cx43 pS368 
appeared to mostly overlap in these images (Fig. 4-3B). 
To get a more detailed picture of the structure of the GJ plaques in myocyte-
fibroblast contacts in these co-cultures, we used gSTED microscopy. However, we 
were unable to obtain images of these punctate plaques in myocyte-fibroblast 
connections as the high laser power used for gSTED microscopy quickly 
extinguished the fluorescent antibody under imaging parameters that allowed 
capture of larger GJ plaques. This technique did allow us to obtain images of larger 
myocyte-myocyte gap junctions (Fig. 4-3C&D). These images revealed a never-
before-seen GJ subdomain organization with respect to non-phosphorylated Cx43 
and Cx43 pS368 (Fig. 4-3C,D,E). Interestingly, co-cultures treated with αCT1 
showed larger GJ plaques, though there did not appear to be a difference in 
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subdomain organization between treated and control cultures. Figure 4-3E shows 
the detail of non-phosphorylated Cx43 and Cx43 pS368 subdomain organization, 
where it appears that these two forms of Cx43 are organized into a mosaic pattern 
in the GJ plaque. 
In order to understand the structure of myocyte-fibroblast Cx43 interactions in adult 
tissue, we used gSTED microscopy to look for this same protein pair in sections of 
cryo-injured adult mouse heart tissue. gSTED was not sufficiently robust to image 
into these tissues, so we repeated this imaging study using a single molecule 
localization technique. Again, we found it difficult to image myocyte-fibroblast 
connections because of their small size. Images obtained of GJ plaques between 
adjacent myocytes in the remote (uninjured) region of the myocardium (Fig. 4-3F) 
displayed a similar GJ subdomain structure to that seen in cultures of neonatal 
myocytes. 
 
Figure 4-3. (Following page) A novel GJ plaque subdomain structure revealed by 
super-resolution imaging. A) Myocytes and fibroblasts interact in culture via Cx43 GJs. 
B) Inset of (A). It appears that the non-phosphorylated form (green) and Cx43 pS368 (red) 
are co-localized when examined with standard confocal microscopy. C&D) αCT1 
increased GJ size at the myocyte-myocyte interface. Cx43 (green) and Cx43 pS368 (red) 
appeared to be organized into a mosaic pattern when imaged with super-resolution 
techniques. E) Inset of (C) via gSTED microscopy. F) Structure of an ID in adult mouse 
heart via single molecule localization technique. 
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4.4   Discussion 
In this chapter, we describe the presence of Cx43 in myocyte-fibroblast 
interactions in our in vitro model of the IBZ and modulation of these interactions by 
the Cx43 mimetic peptide αCT1. In the IBZ model, total Cx43 and Cx43 that is 
phosphorylated at serine 368 were found to be significantly increased by treatment 
with the αCT1 peptide in vitro. Subsequent examination of these interactions by 
returning to the cryo-injury model of infarction suggested that αCT1 may alter 
interactions in the IBZ to some extent in vivo as well. In light of these increased 
myocyte-fibroblast interactions via Cx43, further examination of Cx43 GJs by 
super-resolution microscopy techniques revealed a never-before-seen subdomain 
organization of the GJ plaque where the non-phosphorylated form of Cx43 and 
Cx43 pS368 organize into a mosaic pattern within the plaque. 
Importantly, the work detailed in this chapter provide further validation of the in 
vitro model of the IBZ and suggest that αCT1 may be an important tool for 
modulating cellular interactions via Cx43. Data from previous chapters suggest 
that this peptide has an overall beneficial effect on modulating arrhythmias, and 
this chapter suggests that one of the cellular mechanisms involved may involve 
Cx43 GJs. 
Studies on the GJ plaque structure indicate that connexons waiting in the non-
junctional perinexus zone are added to the GJ from the edge of the plaque. It is 
thought that Cx43 is inserted into the membrane mostly unphosphorylated and 
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connexin incorporation into GJ plaques is associated with increasing 
phosphorylation. In light of the novel GJ plaque sub-domain organization described 
in this chapter, connexons may be either differentially phosphorylated by PKC at 
S368 as they are inserted into the cell membrane, resulting in a mosaic pattern as 
they are incorporated into the plaque, or they are differentially phosphorylated as 
sub-domains within the GJ plaque. Studies on trafficking of Cx43 may provide 
more insight into the GJ phosphorylation sub-domain organization. 
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CHAPTER 5:  IMMUNE MODULATION FOR IMPROVED SURVIVAL AND 
ENGRAFTMENT OF STEM CELLS FOR SKELETAL MUSCLE 
REGENERATION 
 
5.1   Introduction 
Though heart muscle and skeletal muscle are both of mesenchymal origin, skeletal 
muscle has remarkable ability to regenerate after injury, while injury to the heart 
typically results in a scar. While numerous populations of muscle stem cells have 
been identified in the skeletal muscle, it is the satellite cell (SC) that is primarily 
responsible for regeneration and muscle re-growth. SCs are normally quiescent, 
contributing to homeostasis of muscle tissue [296]. When muscle is injured, SCs 
are activated by various signals [297], proliferate, and fuse to generate mature 
myofibers [298] that replace lost or damaged muscle. There is, however, a limit to 
the regenerative capacity of muscle. In volumetric muscle loss (VML), which 
typically occurs from injuries due to traumatic accidents or explosions like those 
seen in the battlefield, large amounts of muscle tissue are lost or damaged and 
scarring of the injured area results [299]. Chronic degenerative diseases like 
muscular dystrophies also involve extensive scarring [300]. These conditions are 
subject to reparative fibrosis, in which muscle does not fully regenerate and is 
partially replaced by scar tissue, leading to impaired muscle function and patient 
disability. 
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Therapies for regeneration of lost or damaged muscle tissue include tissue 
engineering approaches with both natural and synthetic scaffold materials 
[301,302], using a variety of cells to either populate scaffolds or inject directly as 
cell-based therapies (Fig. 5-1) [302–305]. For the purpose of this project, we have 
focused on cell-based therapies, which allow the biochemical and biophysical 
signals from the tissue environment to direct regeneration. Cell-based therapies 
are challenged by low survival of implanted cells – typically, only 5-10% of cells 
survive. This low survival rate would require an extremely large number of cells to 
be injected in order to regenerate a large amount of tissue, resulting in high cost 
of these therapies. 
One factor influencing the low survival rate of implanted cells, especially in non-
autologous therapies, is the immune system attack and destruction of these cells. 
Major histocompatibility complex class I (MHC-I) molecules are expressed by all 
cells in the body. In healthy cells, the MHC-I molecules presented are derived from 
the cell’s own proteins, so the immune system recognizes these cells as ‘self.’ 
When infected, the cell presents some molecules derived from the proteins of the 
pathogen, which activates cytotoxic T lymphocytes against those proteins and 
results in killing of the infected cell [306]. 
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Bone marrow mesenchymal stem cells (BMSCs) are thought to be an ‘immune-
privileged’ cell type, making them a good candidate for increasing survival in cell-
based therapies [307]. BMSCs express intermediate levels of MHC-I and lack 
MHC-II entirely, enabling them to evade the immune system in allogeneic 
transplantation [308]. Additionally, BMSCs are known to differentiate into multiple 
Figure 5-1. Cell sources and regenerative strategies for skeletal muscle. A variety of 
cell sources are used for experimental muscle regeneration, including those derived from 
the muscle itself, as well as sources outside the muscle, like bone marrow and adipose 
tissue. These cells can be cultured in vitro on various substrates to form tissue engineered 
muscle for transplantation. Cell may also be modified genetically and expanded in culture 
for transplantation in vivo. 
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tissue types, including muscle [309–312], and have been shown to have modest 
beneficial effects on healing of the heart after MI. While BMSCs can evade immune 
system attack to some extent, other studies report that rejection of these cells does 
occur, and it is likely because of MHC-I mismatch between the donor and recipient 
[313,314]. 
Human cytomegalovirus (HCMV) is ubiquitously expressed in humans. It has 
developed strategies to evade the immune system by downregulating MHC-I 
surface molecules through production of proteins that code for the Unique Short 
(US) region of the HCMV genome [315,316]. Human BMSCs genetically 
engineered to express these US proteins have downregulated surface levels of 
MHC-I, are protected against NK killing, and result in a 1.5 fold to 1.8 fold increase 
in engraftment when implanted in fetal sheep [317]. These results suggest that 
modulating MHC-I expression is a viable strategy for reducing immune system 
response to implanted cells and increasing their survival. 
The goal of these studies was to improve survival and engraftment of satellite cells 
implanted for cell-based skeletal muscle regeneration. Here we describe 
genetically engineered rat BMSCs expressing human US proteins as a proof of 
principal of downregulation of MHC-I. We have also engineered a skeletal muscle 
satellite cell line to express human US proteins, though further examination is 
required. This method of decreasing the immune response is novel to the field of 
skeletal muscle regeneration, but has been used in other fields. 
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5.2   Methods 
Animal care and use: All animal research was conducted under the guidance of 
the Institutional Animal Care and Use Committee of Virginia Polytechnic and State 
University and conforms to the NIH Guide for the Care and Usage of Laboratory 
Animals.  
BMSC isolation and culture: Bone marrow mesenchymal stem cells were isolated 
from adult rat femurs. Femur heads were clipped off using bone reamers, and 
DMEM medium was used to flush the bone marrow cavity with a syringe and 22 
gauge needle. Bone marrow was collected into a 15 mL conical tube. Cells were 
triturated and plated on 100 mm dishes. Non-adherent cells were removed after 
24 hours. Cells were passaged no more than 5 times in DMEM (Hyclone) 
supplemented with 10% FBS (Hyclone), 10 U/ml penicillin and 10 µg/ml 
streptomycin (Hyclone), and 2 mM L-alanyl-L-glutamine (Fisher) and maintained 
in an incubator at 37°C, 5% CO2. 
H2K cell culture: H2K cells [318,319] were isolated by Terry Partridge’s lab at the 
Children’s National Medical Center in Washington, DC. H2K cells were grown to a 
density of 10,000/cm2 in DMEM (Hyclone) supplemented with 20 U/mL IFN-γ 
(Millipore), 20% HI-FBS (Atlanta Biologicals), 2% chick embryo extract (Accurate 
Chemical), 2 mM L-alanyl-L-glutamine (Fisher), 10 U/ml penicillin and 10 µg/ml 
streptomycin (Hyclone) and maintained in an incubator at 33°C, 10% CO2. 
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PT67 cell culture: PT67 cells transfected with constructs for HCMV Unique Short 
(US) proteins US2, US3, US6, US11, and an empty vector were a gift from the lab 
of Dr. Graça Almeida-Porada at the Wake Forest Institute for Regenerative 
Medicine. Briefly, US2, US3, US6, and US11 DNA sequences were PCR amplified 
from a clinical HCMV isolate, introducing EcoRI and XhoI restriction sites for US3, 
US6, and US11 and EcoRI and SalI for US2. The purified PCR products were then 
ligated into the pMSCV-Neo retroviral vector backbone (Clontech, Mountain View, 
CA) that had been previously digested with EcoRI and XhoI. These recombinant 
plasmids were transformed into One Shot Top10 chemically competent cells (Life 
Technologies), and transformed Top10 cells were selected with ampicillin (Sigma; 
50 µg/mL). Positive clones were confirmed by PCR using primers for the US insert, 
miniprep digestions, and sequencing. For US3, US6, and US11 cloning, digestion 
was performed with EcoRI and XhoI restriction enzymes. For US2 cloning, EcoRI 
and BglII restriction sites were digested, as US2 cloning generated a SalI/XhoI 
hybrid restriction site. Each US recombinant plasmid and an empty plasmid were 
transfected into the RetroPack™ PT67 Packaging Cell Line (Clontech) using 
Lipofectamine 2000 (Life Technologies) according to the manufacturer’s 
instructions. Stable transfectants were selected for 5 days with 500 µg/mL G418 
(Fisher), starting at 72 hours after the transfection. Supernatants were collected 
and filtered with 0.2 µm low protein binding syringe filters (Pall Corporation, Ann 
Arbor, MI). PT67 cells are cultured in DMEM (Hyclone) supplemented with 10% 
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FBS (Hyclone), 10 U/ml penicillin and 10 µg/ml streptomycin (Hyclone), and 2 mM 
L-alanyl-L-glutamine (Fisher) and maintained in an incubator at 37°C, 5% CO2. 
BMSC transduction: Subconfluent cultures of BMSCs were transduced for 6 hours 
with filtered supernatant containing either US recombinant or empty MSCVneo 
retrovirus diluted in serum-free QBSF60 medium (Quality Biological, Gaithersburg, 
MD) and 8 µg/mL protamine sulfate (Calbiochem, San Diego, CA). After 
transduction, stable US-recombinant BMSCs were selected with 500 µg/mL G418 
(Fisher) for 5 days, replacing the selection media every 2 to 3 days. Therefore, 
after the antibiotic selection, all the cells were transduced and consequently 
expressing NeoR and the corresponding US HCMV gene. 
H2K cell transduction: Subconfluent cultures of H2K cells were transduced for 6 
hours with filtered supernatant containing either US recombinant or empty 
MSCVneo retrovirus diluted in serum-free QBSF60 medium (Quality Biological, 
Gaithersburg, MD) and 8 µg/mL protamine sulfate (Calbiochem, San Diego, CA). 
After transduction, stable US-recombinant H2K cells were selected with 500 µg/mL 
G418 (Fisher) for 5 days, replacing the selection media every 2 to 3 days. 
Therefore, after the antibiotic selection, all the cells were transduced and 
consequently expressing NeoR and the corresponding US HCMV gene. 
Transmitted light images of transduced and untransduced H2K populations were 
captured on a Life Technologies EVOS FL microscope. 
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Flow cytometry analysis: BMSC, BMSC-E, BMSC-US2, BMSC-US3, BMSC-US6, 
and BMSC-US11, prior to confluence, were detached by cell scraping in 1x PBS, 
in order to preserve extracelluluar epitopes. Cells were counted and their viability 
checked using Trypan Blue reagent. 1x106 cells were incubated for 15 minutes at 
room temperature with FITC-tagged mouse anti-rat RT1A (BD Pharmingen™, 
Clone OX-18) or FITC-tagged mouse IgG1ϰ isotype control antibodies. Cells were 
washed, fixed with 0.1% azide in PBS, centrifuged and fixed with 1% 
paraformaldehyde. Forward and side scatter plots were generated and used to 
exclude the few dead cells and debris from the histogram analysis plots. 
 
5.3   Results 
HCMV US proteins downregulate MHC-I on rat bone marrow MSCs 
Rat bone marrow MSCs were transduced with retroviral vectors expressing US2, 
US3, US6, and US11. Non-transduced BMSCs and BMSCs transduced with an 
empty vector (BMSC-E) were used as controls. 48 hours after transduction, 
BMSCs were selected with 500 µg/mL G418 for 5 days with media changes every 
2 to 3 days. Only cells expressing neomycin resistance (NeoR), and hence, the 
expression vector for the protein of interest, survived. The morphology of the 
BMSCs was not changed by transduction with the US protein constructs (data not 
shown). 
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Expression of MHC-I was measured by flow cytometry in cells transduced with US 
proteins and their controls. Scatter plots of BMSCs from the initial experiment are 
shown in Figure 5-2 with isotype controls subtracted. Figure 5-2B summarizes the 
percentage of MHC-I positive cells with Median Fluorescent Intensity (MFI) ratios 
in Figure 5-2C. MFI ratio was obtained by dividing MHC-I’s MFI by the respective 
isotype’s MFI. Transduction of BMSC with MSCVneo empty retroviral vector 
resulted in a decrease in the percentage of transduced cells expressing MHC-I 
from 94.75% to 76.45%. Transduction of BMSCs with US6 and US2 resulted in the 
largest decrease in surface expression of MHC-I to 62.45% and 68.36%, 
respectively. This represented a ~34% and a ~28% decrease, respectively. This 
reduction in MHC-I expression was also reflected in the decreased MFI ratio in 
US6 and US2 transduced cells (Fig. 5-2C). Transduction of BMSCs with US3 and 
US11 also resulted in decreased MHC-I expression, though to a lesser extent 
(74.64% and 75.04%, respectively). 
 
H2K cells can be transduced and selected for US-protein expression 
H2K cells were transduced with retroviral vectors expressing US2, US3, US6, and 
US11. Non-transduced H2K cells and H2K cells transduced with an empty vector 
(H2K-E) were used as controls. 48 hours after transduction, H2K cells were 
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selected with 500 µg/mL G418 for 5 days with media changes every 2 to 3 days. 
Only cells expressing neomycin resistance (NeoR), and hence, the expression 
vector for the protein of interest, survived. The morphology of the H2K cells was 
not changed by transduction with the US protein constructs (Fig. 5-3). 
 
Fig 5-2 
Figure 5-2. Forced expression of human US proteins in rat BMSCs reduced cell 
surface presentation of MHC-I. A) Flow cytometry scatter plots showed reduced MHC-I 
presentation by ~30% in US2 and US6, which is reflected in (B). C) The median 
fluorescent intensity ratio reflects the alteration in MHC-I surface expression. 
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5.4   Discussion 
Satellite cells have the ability to regenerate lost muscle tissue, though VML and 
muscular dystrophies typically result in scarring that can inhibit muscle function. 
Satellite cells have been used for tissue engineering and cell-based regenerative 
medicine approaches, but these therapies are challenged by low survival and 
engraftment of injected cells. One of the reasons for low cell survival is attack of 
the implanted cells by the immune system, in particular, MHC-I molecule mismatch 
between the donor and the recipient [313,314]. Previous studies have shown that 
Figure 5-3. H2K cells can be transduced with US protein viral constructs with no 
change to their morphology. Cells under selection with G418 have several rounded, 
dying cells that were not transduced. 
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downregulation of MHC-I molecules through US protein expression can improve 
cell survival [317]. 
Here, we demonstrated proof of principal of downregulation of MHC-I on rat 
BMSCs, resulting in ~30% decrease in cell surface levels of MHC-I molecules. 
Additionally, we transduced H2K cells with US protein constructs and selected for 
cells expressing the constructs. Further work needs to be done to examine the 
relative levels of MHC-I on H2K cells by flow cytometry. Additionally, studies of 
survival and engraftment need to be completed. H2K cells are particularly well-
suited to studies of this type, as they are a conditionally immortal cell type 
[319,320]. These cells, isolated from the H-2Kb-tsA58 immortomouse, have a 
temperature sensitive immortalizing gene, where at lower temperatures the cells 
are continually mitotic, and at higher temperatures the cells terminally differentiate 
and fuse into myotubes [319,320]. 
The immortomouse system provides the highest reproducibility across animal 
experiments, as cells from a single isolation can be expanded extensively in 
culture, eliminating variability due to multiple isolation of primary cells. For animal 
implantation models, cell death and regeneration can be measured using the Y 
chromosome – which is conserved in the immortomouse system, proving a distinct 
advantage over other mouse cell lines. 
Cell-based therapies for MI have included both satellite cells [321,322] and bone 
marrow cells [272]. Satellite cells, a muscle progenitor, were believed to be a good 
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candidate for differentiation into a contractile cell phenotype that would confer 
functionality to the infarcted myocardial scar [323]. In addition to their ability to 
differentiate into muscle cells, these cells can be easily expanded in vitro, are 
resistant to ischemia, and have a low risk of tumorigenesis [6]. Studies of this kind 
have been met with only moderate success due to the inability of satellite cells to 
efficiently transdifferentiate into a cardiomyocyte-like phenotype [324,325]. 
The studies completed and outlined here examine the development of a technique 
that can modulate the immune response to cells implanted for regenerative 
therapies with the goal of improving survival and engraftment of cells.  
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CHAPTER 6:  CONCLUSIONS 
 
6.1   Summary 
Cardiovascular disease is the leading cause of death worldwide. Myocardial 
infarction – a subset of CVD – is responsible for over 150,000 deaths each year in 
the United States alone [3]. Current clinical therapies for MI are focused on 
prolonging life and few new drugs make it to market due to the inefficiencies in the 
drug development pipeline. In order to get more efficacious drugs to patients faster 
with a focus on improving cardiac function and regenerating tissue lost to the 
ischemic insult, there is a need for better platforms for testing of new therapeutics. 
The IBZ is frequently the site of lethal reentrant arrhythmia generation, likely 
caused by the changes in cellular and molecular remodeling that occur after MI 
[11,233]. Alterations in patterns of organization of myocytes and fibroblasts, 
increased fibrosis, and changes in localization of Cx43 are all thought to contribute 
to the generation of a pro-arrhythmic substrate, though the mechanism of each of 
these is not fully understood. 
The major focus of my work is the development and validation of an in vitro model 
of the IBZ with the goals of generating a disease-relevant and tissue structure-
relevant model that can be used for high-throughput in vitro testing of therapeutic 
compounds to target the arrhythmogenic propensity of the IBZ and utilizing this 
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model to gain a better understanding of heterocellular interactions in the IBZ. The 
research presented in this dissertation has generated novel contributions to the 
fields of drug development and mechanistic targets for cardiac regenerative 
therapies. 
In chapter 2 we developed a novel in vitro model of the IBZ. This model 
recapitulates disease-relevant alterations in cell organization in response to the 
small peptide therapeutic (αCT1) reported in previous studies of cardiac cryo-injury 
from our lab [231], and suggests an adhesive role for Cx43 in this process. Of 
relevance to drug discovery is the generation of a high-throughput 3D model, which 
is more tissue-relevant than the 2D in vitro testing paradigms often used prior to 
pre-clinical animal models. Other experimental in vitro models of cardiovascular 
disease have been used to test drugs, though these platforms are not widely used, 
have not been standardized, and have not been validated against disease or drug 
responses [195]. To our knowledge, none of these is an image-based platform. 
Our novel in vitro model advances the field of drug development by providing a 
model relevant to tissue that can be validated against disease and drug responses. 
Additionally, it is the first model of its kind used to examine cell interactions in real 
time. 
In chapter 3 we described a delay in action potential propagation through the cryo-
IBZ in conditions of altered extracellular ion concentrations, though acutely treating 
cryo-injured hearts with αCT1 abolished this delay when measured in 8-week 
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healed hearts. A communication assay suggested that αCT1 decreased GJIC in 
myocyte-fibroblast interactions and in fibroblast-fibroblast interactions. Our studies 
of recruited bone marrow cells to the cardiac infarct did not yield conclusive results 
and further testing is needed. Previous studies describe conduction slowing 
through the IBZ, though none have directly measured the delay in action potential 
propagation. Since this delay was induced by altered extracellular ion 
concentrations, these data suggest the possible influence of ephaptic coupling 
mechanisms in the IBZ. Studies from our lab demonstrate the presence of cardiac 
myocyte ephaptic coupling [120], though modeling studies suggest that ephaptic 
effects may be present in any intercellular space, indicating a possible role for 
fibroblasts in ephaptic coupling in the IBZ, though this requires further 
investigation.  
Previous studies from our lab showed that αCT1 treatment of cryo-injured hearts 
resulted in an increase in phosphorylation at serine 368 of Cx43 (pS368) [104,105], 
which decreases unitary conductance of the GJ channel. Consistent with this, we 
show here that elevated Cx43 pS368 level correlates with reduction of intercellular 
communication between cultured myocytes and cardiac fibroblasts. Our studies 
also suggest that increased Cx43 pS368 corresponds to increased uniformity of 
action potential propagation through the IBZ [104]. This property may relate to the 
decreases in arrhythmic propensity observed in cryo-injured hearts [326]. This 
being said, the mechanism by which αCT1 improves the physiological metrics of 
injured hearts requires further investigation. 
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In chapter 4 we investigated how Cx43 heterocellular interactions changed when 
treated with αCT1. Cx43 and Cx43 pS368 are increased in myocyte-fibroblast 
interactions in our in vitro model. Super-resolution imaging techniques revealed a 
never-before-seen Cx43 GJ plaque sub-domain organization in which non-
phosphorylated Cx43 and Cx43 pS368 are arranged in a mosaic pattern. Studies 
exist indicating the presence of myocyte-fibroblast coupling via Cx43 in both the 
normal and diseased heart, though presence of protein does not imply function. 
Cx43 pS368 is associated with decreased channel conductance. Our studies 
suggest that αCT1 increases myocyte-fibroblast interactions via Cx43, though it is 
possible that communication is reduced, since there is also a significant increase 
in Cx43 pS368 with αCT1 treatment.  
Studies on the GJ plaque structure indicate that connexons waiting in the non-
junctional perinexus zone are added to the GJ from the edge of the plaque. It is 
thought that Cx43 is inserted into the membrane mostly unphosphorylated and 
connexin incorporation into GJ plaques is associated with increasing 
phosphorylation. In light of the novel GJ plaque sub-domain organization reported 
herein, the data suggests that connexons are either differentially phosphorylated 
by PKC at S368 as they are inserted into the cell membrane, resulting in a mosaic 
pattern as they are incorporated into the  GJ plaque, or they are differentially 
phosphorylated as sub-domains within the GJ plaque. Further trafficking, 
interaction, and biophysical studies are required to better understand how this 
phosphorylation sub-domain organization arises. An enhanced understanding of 
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functional coupling in the IBZ may enable development of improved therapies to 
reduce arrhythmias in post-MI patients. 
In chapter 5 we explored proof-of-concept of reducing immune system recognition 
of cells through decreased MHC-I molecule surface presentation in BMSCs and 
H2K satellite cells for application in cell-based regeneration of skeletal muscle. We 
found that expression of MHC-I surface presentation could be reduced by ~30% 
on BMSCs and that H2K cells could be efficiently transduced with US proteins. 
Other studies have used US protein expressing BMSCs as a cell-based 
regenerative therapy  and shown a 1.5- to 1.8-fold improvement in cell engraftment 
using these strategies [317]. Though further work in animal models needs to be 
undertaken to assess the utility of this strategy for regeneration of skeletal muscle, 
these studies provided proof-of-concept. While other skeletal muscle regeneration 
studies have utilized BMSCs for cell-based therapy, and BMSCs are known to 
contribute to skeletal muscle regeneration, none have used the approach of 
directly modulating the immune system for improved survival and engraftment of 
cells. These studies have the potential to advance the field by reducing cost and 
improving the effectiveness of cell-based therapies, leading to reduced scarring 
and improved patient outcomes.  
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6.2   Challenges and limitations 
Cell source 
In vitro models are limited by cell source. Our model uses neonatal rat ventricular 
myocytes and fibroblasts, which are easy to isolate, but do not necessarily have 
the same connexin distribution as adults heart. Post-natal cardiac development 
includes the progressive formation of brick-shaped myocytes with IDs and 
adhesion junctions at the short ends of the cell and lower amounts of connexin at 
lateral cell borders. Additionally, there are interspecies differences in cardiac 
electrophysiological properties, and these have been responsible for removal of 
FDA-approved drugs from the market due to previously unseen cardiotoxic effects. 
Isolated human cells provide an electrophysiologically germane model, but are 
difficult to obtain and maintain in culture. Large animal models like sheep and pig 
are more relevant in terms of size and physiology than are rodents, but these are 
expensive models. Human iPSCs have been increasingly used to model genetic 
mutations affecting cardiac function, and may be a good source for in vitro model 
development as well, though these cells are challenged by their limited ability to 
take on a mature cardiomyocyte phenotype. 
The field of cell-based regenerative medicine has been challenged by cell source 
from the beginning. Ideally, cell-based therapies would use autologous cells to 
reduce the effect of the immune response, though this also requires development 
of serum-free culture technologies for cell expansion. Expansion of human stem 
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cells in culture is slow and requires Good Laboratory Practice (GLP) facilities, 
making these therapies costly. Use of non-autologous therapies requires immune 
modulation of the implanted cells or engineered tissues or requires patient 
immunosupression. 
 
Disease-relevant animal models 
Our in vitro model was developed using rat cells and validated against a mouse 
model of MI. While these models have been developed to closely represent human 
pathologies, they do not fully recapitulate human disease processes. Development 
of safe and effective pharmaceuticals would be improved by development of more 
disease-relevant and tissue-relevant models. 
 
6.3   Future directions and recommendations 
The in vitro IBZ model can be expanded and altered to meet the testing need, 
including examination of other cell types and different compounds. For genetic 
disease-relevant models, use of iPSCs from patients carrying a cardiac genetic 
mutation would allow development of therapeutics for those specific diseases. 
Perfusion bioreactor systems could be generated to fit the multi-well agarose 
micromolds currently used, especially if the candidate compound will be delivered 
systemically when used in the clinic. For local delivery, studies using cryo-injury 
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model in our lab used a methylcellulose patch to deliver αCT1, though this patch 
does not adhere tightly to the surface of the heart. If a candidate compound is 
targeting a specific time point in the healing process, developing a delivery system 
or a controlled release system would be pertinent. 
Cell organization data in the cryo-IBZ model [231], as well as the work in our in 
vitro model (Chapter 2) suggested a difference in cell cohesion was evident at a 
100 µM dose of αCT1. Though a dose curve was not tested in either the in vitro 
aggregate model or the cryo-injury model, the results of the in vitro model reflected 
those of the in vivo model, suggesting that this may be a good starting 
concentration for clinical testing of this drug. Previous work from the lab suggests 
that fibroblast migration in scratch-wound assays increases in a dose-dependent 
manner with αCT1 treatment, encompassing a range of 1 to 180 µM [327], though 
further testing will be required to determine a minimum effective dose. 
Optical mapping of cryo-injured hearts showed that αCT1 altered conduction in the 
IBZ and this may be a result of changes in GJIC, as αCT1 reduced GJIC in 
heterocellular myocyte-fibroblast connections and in homocellular fibroblast cell-
cell connections. This suggests that GJIC is likely altered in the IBZ, though the 
mechanism remains to be understood. Studies of functional myocyte-fibroblast 
coupling in the IBZ would be pertinent to determining how αCT1 affects 
heterocellular interactions in the IBZ. No functional coupling studies in the 
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diseased heart have been published to date. Only one study exists in normal heart, 
and it demonstrates presence of functional myocyte-fibroblast dye coupling [285]. 
Transfer of αCT1 to heart disease and myocardial infarction patients may initially 
involve the testing described above. Additionally, this peptide has completed 
Phase I and Phase II clinical trials for wound healing in chronic non-healing 
diabetic foot ulcers [180] and venous leg ulcers [181], where, among other results, 
this peptide was proven safe and effective on these skin wounds. The clinical 
progress attained in skin would speed up the time to clinic of this peptide for MI 
patients, though, efficacy dose testing would be critical before this peptide could 
be FDA approved. It would also be important to consider delivery methods. We 
use a patch for the cryoinjury procedure in mice, but it is rare that a patient’s chest 
is opened when they present in the clinic with symptoms indicating MI. While 
systemic delivery is a simple option, this must be critically evaluated for the effect 
of the peptide on other tissues and organs in the body. Localized catheter delivery 
may be a possibility, and could be combined with endovascular procedures aimed 
at opening the coronary arteries. 
Our study of bone marrow recruitment to the cardiac injury did not yield conclusive 
results, but did raise a number of questions about the model. Measuring the 
transduction efficiency of the injection of virus in the bone marrow cavity would 
enable assessment of whether recruitment is being challenged by low transduction 
efficiency or low cell homing to the cryo-injured heart. Additionally, bone marrow 
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chimeras may be a more robust approach to this question, as there is no transgenic 
BMSC mouse due to lack of a specific marker for these cells. 
As discussed in Chapter 5, H2K satellite cell US protein transduction studies 
should be assessed for MHC-I surface presentation, and, pending results, taken 
into animal models of survival and engraftment, using the Y-chromosome to track 
these cells post-implantation. These studies may hold promise for translation to 
clinical therapies if MHC-I presentation can be sufficiently suppressed to allow 
better survival and engraftment of SCs for therapies in muscle loss or dystrophic 
disease.  
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